Document:

Form of Registration Rights Agreement

 Exhibit 4.13 
 AMENDED AND RESTATED 
 REGISTRATION RIGHTS AGREEMENT 
 This Amended and Restated Registration Rights Amendment (this “Amended and Restated Agreement”), which amended and restates in its
entirety the Registration Rights Agreement among the parties hereto (the “Agreement”), is made and entered into as of March __, 2006, by and among Synova Healthcare Group, Inc., a Nevada corporation (the “Company”), and
the purchasers signatory hereto (each such purchaser, a “Purchaser” and collectively, the “Purchasers”). 
 WHEREAS, pursuant to Section 6(e) of the Agreement, the parties desire to amend and restate all of the terms, conditions and provisions of the Agreement in their entirety as set forth herein. 
 NOW, THEREFORE, in consideration of the mutual promises of the parties hereto and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereby agree as follows: 
 1.
Definitions. Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the
following meanings: 
 “Advice” shall have the meaning set forth in Section 6(c). 
 “Agreement” shall refer to this Amended and Restated Registration Rights Agreement, as it may be amended or modified. 
 “Commission” means the United States Securities and Exchange Commission or its successor federal agency. 
 “Effectiveness Period” shall have the meaning set forth in Section 2(a). 
 “Effective Date” means, with respect to the Registration Statement required to be filed hereunder, the date that the Registration Statement is
declared effective by the Commission. 
 “Electing Holder” shall have the meaning set forth in Section 3(a). 
 “Filing Date” means, with respect to the Registration Statement required to be filed hereunder, the date that the Registration Statement is
first filed with the Commission. 
 “Holder” means any person that is the record owner of Registrable Securities (and includes any
person that has a beneficial interest in any Registrable Security in book-entry form). 
 “Holders” mean every Holder collectively.

 “Indemnified Party” shall have the meaning set forth in Section 5(c). 
 “Indemnifying Party” shall have the meaning set forth in Section 5(c). 
 “Losses” shall have the meaning set forth in Section 5(a). 

 “Proceeding” means an action, claim, suit, investigation or proceeding (including, without
limitation, an investigation or partial proceeding, such as a deposition), whether commenced or threatened. 
 “Prospectus” means
the prospectus included in the Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A
promulgated under the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by the Registration Statement, and all other amendments
and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus. 
 “Registrable Securities” means all of the Shares and the Warrant Shares sold under the Purchase Agreement, together with any shares of Common
Stock issued or issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing. 
 “Registration Statement” means the registration statements required to be filed hereunder, including (in each case) the Prospectus, amendments and supplements to the registration statement or Prospectus, including pre- and
post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in the registration statement. 
 “Rule 415” means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission
having substantially the same purpose and effect as such Rule. 
 “Rule 424” means Rule 424 promulgated by the Commission pursuant
to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. 
 2. Registration. 
 (a)
On or prior to April 14, 2006, the Company shall prepare and file with the Commission the Registration Statement covering the resale of all of the Registrable Securities for an offering to be made on a continuous or delayed basis pursuant to
Rule 415. The Registration Statement required hereunder shall be on such form as permitted by the rules and regulations of the Commission which permits the sale of the Registrable Securities by the Holders. The Registration Statement required
hereunder shall contain (except if otherwise directed by the Holders or as otherwise directed or requested by the Commission or required by applicable law, rule or regulation) substantially the “Plan of Distribution” attached hereto as
Annex A. Subject to the terms of this Agreement, the Company shall use its commercially reasonable efforts to cause the Registration Statement to be declared effective under the Securities Act as promptly as possible after the filing thereof,
but in any event not later than June 28, 2006, and shall use its commercially reasonable efforts to keep the Registration Statement continuously effective under the Securities Act until the earliest of (i) the date when all Registrable
Securities covered by the Registration Statement have been sold; (ii) the expiration of the period referred to Rule 144(k) of the Securities Act with respect to all Registrable Securities held by persons that are not Affiliates of the Company;
(iii) two years from the Effective Date; or (iv) no Registrable Securities are outstanding (the “Effectiveness Period”). 
 (b) Notwithstanding anything to the contrary contained in this Agreement, the Company may (i) upon written notice to all Holders, postpone having the Registration Statement declared effective for a reasonable
period not to exceed 30 days if the Company possesses material non-public information, the disclosure of which would have a material adverse effect on the 

  

 2 

 
Company and its subsidiaries taken as a whole or would impede the consummation of a proposed or pending material business transaction; provided, however,
that such postponement shall be subject to the liquidated damages required under Section 2(c) or (ii) suspend the use of the Prospectus for a period not to exceed 15 days in any 30-day period or an aggregate of 30 days in any 12-month
period if the Board of Directors of the Company shall have determined in good faith that because of valid business reasons (not including avoidance of the Company’s obligations hereunder), including without limitation the acquisition or
divestiture of assets, pending material corporate developments and similar events, it is in the best interests of the Company to suspend such use, and prior to suspending such use the Company provides the Electing Holders with written notice of such
suspension, which notice need not specify the nature of the event giving rise to such suspension. If the Company makes a postponement or a suspension pursuant to the terms of clause (ii) of this Section 2(b), the partial liquidated damages
set forth in Section 2(c) shall not apply to any such postponement or suspension until the time periods set forth in Section 2(b)(ii) have been exceeded; provided, however, that the Electing Holders shall not be entitled to any liquidated
damages under Section 2 if use of the Prospectus was suspended under Section 2(b)(ii) in connection with negotiations relating to a sale (regardless of the form) of the Company and such negotiations result in a sale (regardless of the
form) of the Company pursuant to which the Holders receive proceeds of at least $1.50 per share. 
 (c) If: (i) a
Registration Statement is not filed on or prior to April 14, 2006 (if the Company files a Registration Statement without affording the Electing Holders the opportunity to review and comment on the same as required by Section 3(a), the
Company shall not be deemed to have satisfied this clause (i)), or (ii) a Registration Statement filed or required to be filed hereunder is not declared effective for any reason by the Commission on or before June 28, 2006, or
(iii) other than during the periods for which the Company gives notice under Section 2(b)(ii), which shall be governed by Section 2(b)(ii), after a Registration Statement is first declared effective by the Commission, it ceases for
any reason to remain continuously effective as to all Registrable Securities for which it is required to be effective, or the Holders are not permitted to utilize the Prospectus therein to resell such Registrable Securities, for in any such case 20
consecutive calendar days but no more than an aggregate of 45 calendar days during any 12 month period (which need not be consecutive Trading Days) (any such failure or breach being referred to as an “Event,” and for purposes of clause
(i) or (ii) the date on which such Event occurs or for purposes of clause (iii) the date on which such 20 or 45 calendar day period, as applicable, is exceeded being referred to as “Event Date”), then in addition to any
other rights the Holders may have hereunder or under applicable law, on the first of such Event Dates, the Company shall pay to each Holder (x) upon the occurrence of such Event, an amount, as partial liquidated damages and not as a penalty,
equal to 1.0% of the aggregate purchase price paid by such Holder pursuant to the Purchase Agreement for any Registrable Securities then held by such Holder, and (y) on each monthly anniversary of such Event Date (if the applicable Event shall
not have been cured by such date), the Company shall pay to each Holder an amount, as partial liquidated damages and not as a penalty, equal to 1.5% of the aggregate purchase price paid by such Holder pursuant to the Purchase Agreement for any
Registrable Securities then held by such Holder. Notwithstanding anything to the contrary herein, if the Commission (or any successor) has an unscheduled closure of operations during any Trading Days prior to or during the Effectiveness Period,
then, as the case may be, any of the periods above shall be tolled for a number of days equal to the number of days in the period beginning on such closure and ending on the Trading Day when the Commission is open for business, or the deadline for
filing or causing the effectiveness of the Registration Statement shall be postponed by such number of days. The partial liquidated damages pursuant to the terms hereof shall apply on a daily pro-rata basis for any portion of a 30-day period prior
to the cure of an Event. In lieu of cash, at the option of the Company, such liquidated damages may be paid in shares of Common Stock valued at 85% of the average ten day trading price for a period ended upon the effectiveness of the Registration
Statement. If the Company pays such liquidated damages to the Holders in shares of Common Stock under this Section, such Holders shall be entitled to “piggy-back” registration rights with respect to such shares of Common Stock pursuant to,
and in accordance with, Section 6(d) of this Agreement; provided, however, that such “piggy-back” registration rights shall not apply with respect to the Registration Statement. 
  

 3 

 3. Registration Procedures. 
 In connection with the Company’s registration obligations hereunder, the Company shall: 
 (a) Not less than five (5) Trading Days prior to the filing of the Registration Statement or any related Prospectus or any amendment
or supplement thereto, the Company shall, (i) furnish to the Holders copies of all such documents proposed to be filed (including documents incorporated or deemed incorporated by reference to the extent requested by such Person) which documents
will be subject to the review of such Holders, and (ii) cause its officers and directors, counsel and independent certified public accountants to respond to such inquiries as shall be necessary, in the reasonable opinion of respective counsel
to conduct a reasonable investigation within the meaning of the Securities Act. The Company shall not file the Registration Statement or any such Prospectus or any amendments or supplements thereto to which the Holders of a majority of the
Registrable Securities shall reasonably object in good faith; provided that the Company is notified of such objection in writing no later than four (4) Trading Days after the Holders have been so furnished copies of such documents. Each Holder
agrees to furnish to the Company a signed and completed Notice and Questionnaire in the form attached to this Agreement as Annex B (a “Selling Holder Questionnaire”) not less than seven (7) Trading Days prior to the
Filing Date or by the end of the fourth (4th) Trading Day following the date on which such Holder receives draft materials in accordance with this Section 3(a). Notwithstanding anything to the contrary contained in this Agreement, no
Holder shall be entitled to be named as a selling securityholder in the Registration Statement as of the Effective Time, and no Holder shall be entitled to use the Prospectus forming a part thereof for offers and resales of Registrable Securities at
any time, unless such Holder has returned a properly completed and signed Selling Holder Questionnaire to the Company by the deadline for response set forth in the foregoing sentence. Any Holder of Registrable Securities that has returned a properly
completed and signed Selling Holder Questionnaire to the Company shall be referred to as an “Electing Holder.” 
 (b)(i) Prepare and file with the Commission such amendments, including post-effective amendments, to the Registration Statement and the Prospectus used in connection therewith as may be necessary to keep the Registration Statement
continuously effective as to the applicable Registrable Securities for the Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement, and as so supplemented or amended to be
filed pursuant to Rule 424; (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect to the Registration Statement or any amendment thereto and, as promptly as reasonably possible, upon request,
provide the Holders true and complete copies of all correspondence from and to the Commission relating to the Registration Statement; and (iv) comply in all material respects with the provisions of the Securities Act and the Exchange Act with
respect to the disposition of all Registrable Securities covered by the Registration Statement during the applicable period in accordance with the intended methods of disposition by the Holders thereof set forth in the Registration Statement as so
amended or in such Prospectus as so supplemented. 
 (c) Notify the Electing Holders as promptly as reasonably possible (but
in any event, within three (3) Trading Days in the case of subparagraphs (i) and (ii) below, and within one (1) Trading Day in the case of subparagraphs (iii), (iv) and (v) below) following the day (i)(A) when a
Prospectus or any Prospectus supplement or post-effective amendment to the Registration Statement is proposed to be filed; (B) when the Commission notifies the Company whether there will be a “review” of the Registration Statement and
whenever the Commission comments in writing on the Registration Statement (the Company shall 

  

 4 

 
upon request provide true and complete copies thereof and all written responses thereto to each of the Holders); and (C) with respect to the
Registration Statement or any post-effective amendment, when the same has become effective; (ii) of any request by the Commission or any other Federal or state governmental authority during the period of effectiveness of the Registration
Statement for amendments or supplements to the Registration Statement or Prospectus or for additional information; (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the
effectiveness of the Registration Statement covering any or all of the Registrable Securities or the initiation of any Proceedings for that purpose; (iv) of the receipt by the Company of any notification with respect to the suspension of the
qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation or threatening of any Proceeding for such purpose; and (v) of the occurrence of any event or passage of time that
makes the financial statements included in the Registration Statement ineligible for inclusion therein or any statement made in the Registration Statement or Prospectus or any document incorporated or deemed to be incorporated therein by reference
untrue in any material respect or that requires any revisions to the Registration Statement, Prospectus or other documents so that, in the case of the Registration Statement or the Prospectus, as the case may be, it will not contain any untrue
statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. 
 (d) Use commercially reasonable efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order suspending the
effectiveness of the Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, at the earliest practicable moment. 
 (e) Furnish to each Electing Holder, without charge, at least one conformed copy of the Registration Statement and each amendment thereto,
including financial statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such Person, and all exhibits to the extent requested by such Person (including those previously
furnished or incorporated by reference) promptly after the filing of such documents with the Commission. 
 (f) Promptly
deliver to each Electing Holder, without charge, as many copies of the Prospectus or Prospectuses (including each form of prospectus) and each amendment or supplement thereto as such Persons may reasonably request in connection with resales by the
Electing Holder, Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement thereto by each of the selling Electing Holders in connection with the offering and sale of the
Registrable Securities covered by such Prospectus and any amendment or supplement thereto, except after the giving on any notice pursuant to Section 3(c). 
 (g) Prior to any resale of Registrable Securities by an Electing Holder, use its commercially reasonable efforts to register by
coordination or cooperate with the selling Electing Holders in connection with the registration (or exemption therefrom) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within
the United States as any Holder reasonably requests in writing, to keep the registration (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in
such jurisdictions of the Registrable Securities covered by the Registration Statement; provided, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company
to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction. 
  

 5 

 (h) If requested in writing by the Electing Holders, cooperate with the Electing Holders
to facilitate the timely preparation and delivery of certificates representing Registrable Securities to be delivered to a transferee pursuant to the Registration Statement, which certificates shall be free, to the extent permitted by the Purchase
Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holders may so request. 
 (i) Upon the occurrence of any event contemplated by Section 3(c)(v), as promptly as reasonably possible, prepare a supplement or
amendment, including a post-effective amendment, to the Registration Statement or a supplement to the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document so that, as
thereafter delivered, neither the Registration Statement nor such Prospectus will contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of
the circumstances under which they were made, not misleading. If the Company notifies the Electing Holders in accordance with clauses (ii) through (v) of Section 3(c) or clause (ii) of Section 2(b) above to suspend the use
of any Prospectus, then the Electing Holders shall suspend use of such Prospectus. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable. 
 (j) Comply with all applicable rules and regulations of the Commission. 
 (k) During any periods that the Company is unable to meet its obligations hereunder with respect to the registration of the Registrable
Securities solely because any Holder fails to timely furnish the Company with the information reasonably requested and necessary for the Company to meet its obligations hereunder, any liquidated damages that are accruing at such time as to such
Holder only shall be tolled and any Event that may otherwise occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company. If such Holder fails to furnish such information to the
Company within seven (7) Trading Days after a written request from the Company, such Holder’s name may be removed or excluded from the Registration Statement or Prospectus forming a part thereof. 
 4. Registration Expenses. All fees and expenses incident to the performance of or compliance with this Agreement by the Company shall be borne by
the Company whether or not any Registrable Securities are sold pursuant to the Registration Statement. The fees and expenses referred to in the foregoing sentence shall include, without limitation, (i) all registration and filing fees
(including, without limitation, fees and expenses (A) with respect to filings required to be made with the trading market on which the Common Stock is then listed or quoted for trading, and (B) in compliance with applicable state
securities or Blue Sky laws), (ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities and of printing prospectuses if the printing of prospectuses is reasonably requested by the
holders of a majority of the Registrable Securities included in the Registration Statement), (iii) messenger, telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability
insurance, if the Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation of the transactions contemplated by this Agreement. In addition, the Company shall
be responsible for all of its internal expenses incurred in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses of its officers and employees performing legal
or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. Except as provided in any of the Transaction
Documents, in no event shall the Company be responsible for any broker or similar commissions or, except to the extent provided for in the Transaction Documents, any legal fees or other costs of the Holders. 
  

 6 

 5. Indemnification. 
 (a) Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold
harmless each Holder, the officers, directors, agents and employees of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers,
directors, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’
fees) and expenses (collectively, “Losses”), as incurred, arising out of or relating to any untrue or alleged untrue statement of a material fact contained in the Registration Statement, any Prospectus or any form of prospectus or
in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of
any Prospectus or form of prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based solely
upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable
Securities and was reviewed and approved by the Holder for use in the Registration Statement, such Prospectus or such form of Prospectus or in any amendment or supplement thereto (it being understood that the Holders have approved Annex A
hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(c)(ii)-(v) or a notice pursuant to Section 2(b)(ii), the use by such Holder of a Prospectus after the Company has
notified such Holder in writing of the suspension and prior to the receipt by such Holder of the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any Proceeding of
which the Company is aware in connection with the transactions contemplated by this Agreement. 
 (b) Indemnification by
Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and
Section 20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based
solely upon: (x) such Holder’s failure to comply with the prospectus delivery requirements of the Securities Act or (y) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus,
or any form of prospectus, or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the
statements therein not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained in any information so furnished in writing to the Company by the Holder specifically for inclusion in the
Registration Statement or such Prospectus or (ii) to the extent that (I) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder expressly for use
therein, or to the extent that such information relates to such Holder or such Holder’s proposed method of distribution of Registrable Securities and was reviewed and approved by the Holder for use in the Registration Statement, such Prospectus
or such form of Prospectus or in any amendment or supplement thereto (it being understood that the Holders have approved Annex A hereto for this purpose) or (2) in the case of an occurrence of an event of the type specified in
Section 3(c)(ii)-(v) or a notice pursuant to Section 2(b)(ii), the use by such Holder of a Prospectus after the Company has notified such Holder in writing of the suspension and prior to the receipt by such Holder of the Advice
contemplated in Section 6(c). In no event shall the liability of any selling Holder hereunder be greater in amount than the dollar amount of the net proceeds received by such Holder upon the sale of the Registrable Securities giving rise to
such indemnification obligation. 
  

 7 

 (c) Conduct of Indemnification Proceedings. If any Proceeding shall be brought or
asserted against any Person entitled to indemnity hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify’ the Person from whom indemnity is sought (the “Indemnifying Party”) in
writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses incurred in connection with defense
thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally
determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have prejudiced the Indemnifying Party. 
 An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but
the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses; (2) the Indemnifying Party shall have failed
promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding; or (3) the named parties to any such Proceeding (including any impleaded parties) include both
such Indemnified Party and the Indemnifying Party, and a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the
Indemnifying Party in writing that it elects to employ separate counsel reasonably satisfactory to the Indemnifying Party at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the
reasonable fees and expenses of one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall
not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party which consent shall not be unreasonably withheld or delayed, effect any settlement of any pending Proceeding in respect
of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding. 
 (d) Contribution. If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified
Party (by reason of public policy or otherwise), then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as
is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative
fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a
material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such action,
statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys’ or other reasonable fees or expenses incurred
by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms. 

(e) Limitation. The parties hereto agree that it would not be just and equitable if contribution pursuant to Section 5(d)
were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(e),
no Holder shall be required to contribute, in the aggregate, any amount in excess of the amount by which the proceeds actually received by such Holder from the sale of the Registrable Securities subject to the Proceeding exceeds the amount of
any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, except in the case of fraud by such Holder. 
  

 8 

 (f) Other Liability. The indemnity and contribution agreements contained in this
Section 5 are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties. 
 6.
Miscellaneous. 
 (a) Remedies. In the event of a breach by the Company or by a Holder, of any of their
obligations under this Agreement, each Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, will be entitled to specific performance
of its rights under this Agreement. The Company and each Holder agree that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further
agrees that, in the event of any action for specific performance in respect of such breach, it shall waive the defense that a remedy at law would be adequate. 
 (b) Compliance. Each Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities
Act as applicable to it in connection with sales of Registrable Securities pursuant to the Registration Statement. 
 (c)
Discontinued Disposition. Each Electing Holder agrees by its acquisition of such Registrable Securities that, upon receipt of a notice from the Company of the occurrence of any event of the kind described in Section 3(c) or a notice
pursuant to Section 2(b)(ii), such Electing Holder will forthwith discontinue disposition of such Registrable Securities under the Registration Statement until such Electing Holder’s receipt of the copies of the supplemented Prospectus
and/or amended Registration Statement or until it is advised in writing (the “Advice”) by the Company that the use of the applicable Prospectus may be resumed, and, in either case, has received copies of any additional or
supplemental filings that are incorporated or deemed to be incorporated by reference in such Prospectus or Registration Statement. The Company will use its commercially reasonable efforts to ensure that the use of the Prospectus may be resumed as
promptly as is practicable. 
 (d) Piggy-Back Registrations. If at any time during the Effectiveness Period there is
not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others
under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any
acquisition of any entity or business or equity securities issuable in connection with the stock option or other employee benefit plans, then the Company may send to each Holder a written notice of such determination and, if within fifteen
(15) days after the date of such notice, any such Holder shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Holder requests to be registered, subject to
customary underwriter cutbacks applicable to all holders of registration rights. 
 (e) Amendments and Waivers. The
provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed
by the Company and Holders of at least 50% of the then-outstanding Registrable Securities, unless the waiver or consent effects only the waiving or consenting of one or more particular Holders, in which case such waiver or consent need only be
signed by such Holder or Holders. 
  

 9 

 (f) Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be made in accordance with the provisions of the Purchase Agreement. 
 (g)
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of each Holder. Each Holder may assign their respective rights
hereunder in the manner and to the Persons as permitted under the Purchase Agreement. 
 (h) Execution and
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any
signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature
were the original thereof. 
 (i) Governing Law. All questions concerning the construction, validity, enforcement and
interpretation of this Agreement shall be determined with the provisions of the Purchase Agreement. 
 (j) Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law. 
 (k)
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set
forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or
substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and
restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 
 (l)
Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning hereof. 
 (m) Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the obligations of any other Holder hereunder, and no Holder shall be
responsible in any way for the performance of the obligations of any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action taken by any Holder pursuant hereto or thereto, shall
be deemed to constitute the Holders as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Holders are in any way acting in concert with respect to such obligations or the transactions
contemplated by this Agreement. Each Holder shall be entitled to protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an additional
party in any proceeding for such purpose. 
 -SIGNATURES ON NEXT PAGES- 
  

 10 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Registration Rights Agreement as
of the date first written above. 
  

					
	SYNOVA HEALTHCARE GROUP, INC.
		
	By:	 	  
		 	Name:	 	Stephen King
		 	Title:	 	Chief Executive Officer

 [SIGNATURE PAGES OF HOLDERS FOLLOWS] 
  

 11 

 [PURCHASER SIGNATURE PAGE TO SYNOVA 
 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT] 
 IN WITNESS WHEREOF, the
undersigned have caused this Amended and Restated Registration Rights Agreement to be duly executed by their respective authorized signatories as of the date first indicated above. 
  

			
	Name of Investing Entity:	 	  

			
		
	Signature of Authorized Signatory of Investing Entity:	 	  

			
		
	Name of Authorized Signatory:	 	  

			
		
	Title of Authorized Signatory:	 	  

			
		
	Email Address of Authorized Entity:	 	  

  

 12 

 Annex A 
 to Amended and Restated Registration Rights Agreement 
 ANNEX A 
 Plan of Distribution 
 The Selling
Stockholders (the “Selling Stockholders”) of the common stock (“Common Stock”) of Synova Healthcare Group, Inc. (the “Company”) and any of their pledgees, assignees and successors-in-interest may,
from time to time, sell any or all of their shares of Common Stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling
Stockholders may use any one or more of the following methods when selling shares: 
  

	 	•	 	 ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

  

	 	•	 	 block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the
transaction; 

  

	 	•	 	 purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

  

	 	•	 	 an exchange distribution in accordance with the rules of the applicable exchange; 

  

	 	•	 	 privately negotiated transactions; 

  

	 	•	 	 settlement of short sales entered into after the date of this prospectus; 

  

	 	•	 	 broker-dealers may agree with the Selling Stockholders to sell a specified number of such shares at a stipulated price per share; 

  

	 	•	 	 a combination of any such methods of sale; 

  

	 	•	 	 through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; or 

  

	 	•	 	 any other method permitted pursuant to applicable law. 

 The Selling Stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”), if available, rather than under this prospectus. 
 Broker-dealers engaged by the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be negotiated. Each Selling Stockholder does not expect these commissions and discounts relating to its
sales of shares to exceed what is customary in the types of transactions involved. 
 In connection with the sale of our Common Stock or
interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The
Selling Stockholders may also sell shares of our Common Stock short and deliver these securities to close out their short positions, or loan or pledge the Common Stock to broker-dealers that in turn may sell these 

 
securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of
one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this
prospectus (as supplemented or amended to reflect such transaction). 
 The Selling Stockholders and any broker-dealers or agents that are
involved in selling the shares may be deemed to be “underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale
of the shares purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any agreement or understanding, directly or indirectly, with
any person to distribute the Common Stock. 
 The Company is required to pay certain fees and expenses incurred by the Company incident to
the registration of the shares. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. 
 Because Selling Stockholders may be deemed to be “underwriters” within the meaning of the Securities Act, they will be subject to the
prospectus delivery requirements of the Securities Act. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule 144 rather than under this prospectus. Each
Selling Stockholder has advised us that they have not entered into any agreements, understandings or arrangements with any underwriter or broker-dealer regarding the sale of the resale shares. There is no underwriter or coordinating broker acting in
connection with the proposed sale of the resale shares by the Selling Stockholders. 
 We agreed to keep this prospectus effective until the
earlier of (i) the date on which the shares may be resold by the Selling Stockholders without registration and without regard to any volume limitations by reason of Rule 144(k) under the Securities Act or any other rule of similar effect or
(ii) all of the shares have been sold pursuant to the prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale shares will be sold only through registered or licensed brokers or dealers if required under
applicable state securities laws. In addition, in certain states, the resale shares may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is
available and is complied with. 
 Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution of
the resale shares may not simultaneously engage in market making activities with respect to our common stock for a period of two business days prior to the commencement of the distribution. In addition, the Selling Stockholders will be subject to
applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of shares of our common stock by the Selling Stockholders or any other person. We will make
copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale. 
  

 A-2 

 Annex B 
 to Amended and Restated Registration Rights Agreement 
 ANNEX B 
 SYNOVA HEALTHCARE GROUP, INC. 
 SELLING SECURITYHOLDER NOTICE AND QUESTIONNAIRE 
 The undersigned beneficial owner of common stock, par value $0.001 per
share (the “Common Stock”), of Synova Healthcare Group, Inc., a Nevada corporation (the “Company”), (the “Registrable Securities”) understands that the Company has filed or intends to file with the
Securities and Exchange Commission (the “Commission”) a registration statement (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the
“Securities Act”), of the Registrable Securities, in accordance with the terms of the Amended and Restated Registration Rights Agreement, dated as of
                    , 2006 (the “Registration Rights Agreement”), among the Company and the Purchasers named therein. A copy
of the Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

 In order to have Registrable Securities included in the Registration Statement (or a supplement or amendment thereto), this Selling
Securityholder Notice and Questionnaire (“Selling Securityholder Questionnaire”) must be completed, executed and delivered to the Company at the address set forth herein for receipt on or before the dates required in the
Registration Rights Agreement. Record or beneficial owners of Registrable Securities who do not properly complete, execute and return this Selling Securityholder Questionnaire by such dates (i) will not be named as selling securityholders in
the Registration Statement and (ii) may not use the Prospectus forming a part thereof for resales of Registrable Securities. 
 Certain
legal consequences arise from being named as a selling securityholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial owners of Registrable Securities are advised to consult their own securities law
counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and the related prospectus. 
 NOTICE 
 The undersigned beneficial owner (the “Selling Securityholder”) of
Registrable Securities hereby elects to include the Registrable Securities owned by him/it and listed below in Item 3 (unless otherwise specified under such Item 3) in the Registration Statement. The undersigned, by signing and returning
this Selling Securityholder Questionnaire, agrees to be bound with respect to such Registrable Securities by the terms and conditions of this Selling Securityholder Questionnaire and the Registration Rights Agreement, as if the undersigned Selling
Securityholder were an original party thereto. 
 Upon any sale of Registrable Securities pursuant to the Registration Statement, the Selling
Securityholder will be required to deliver to the Company the Notice of Transfer (completed and signed) set forth in Exhibit 1 to this Selling Securityholder Questionnaire. 

 The undersigned hereby provides the following information to the Company and represents and warrants that
such information is accurate and complete: 
 QUESTIONNAIRE 
  

	1.	Name. 

  

	 	(a)	Full Legal Name of Selling Securityholder (if a limited partnership, state the names of the general partners of such limited partnership): 

                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

	 	(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities Listed in Item 3 below are held: 

                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

	 	(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by the
questionnaire): 

                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

	2.	Address for Notices to Selling Securityholder. 

                                       
                                        
                                        
                                        
                                        
                                        
           
                                       
                                        
                                        
                                        
                                        
                                        
           
  

			
	 Telephone:
	  	                                      
                                        
                                        
                                        
                                        
                        
		
	 Email:
	  	                                      
                                        
                                        
                                        
                                        
                        
		
	 Fax:
	  	                                      
                                        
                                        
                                        
                                        
                        
		
	 Contact Person:
	  	                                      
                                        
                                        
                                        
                                        
                        

  

	3.	Beneficial Ownership of Securities. 

 Except as set
forth below in this Item (3), the undersigned Selling Securityholder does not beneficially own any securities or shares of Common Stock issued upon conversion of any securities. 
  

 2 

	 	(a)	Number of Registrable Securities (as defined in the Registration Rights Agreement) beneficially owned: 

                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

 Number of shares of Common Stock (if any) issued upon conversion of securities: 
                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

	 	(b)	Number of securities of the Company other than Registrable Securities beneficially owned: 

                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

 Number of shares of Common Stock (if any) issued upon conversion of such other securities: 
                                       
                                        
                                        
                                        
                                        
                                        

  

	 	(c)	Number of Registrable Securities to be included in the Registration Statement (Unless otherwise indicated below, all Registrable Securities listed in response to Item (3)(a) above
will be included in the Registration Statement): 

                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

 Number of shares of Common Stock (if any) issued upon conversion of Registrable Securities which are to be included in the Registration
Statement: 
                                       
                                        
                                        
                                        
                                        
                                        

  

	 	(d)	Except as set forth above in this Item (3), the undersigned Selling Securityholder is not the beneficial or record owner of any shares of Common Stock or any other security of the
Company. 

 Yes     ̈                No     ̈ 
  

	 	(e)	If the undersigned Selling Securityholder is the beneficial or record owner of any shares of Common Stock or any other security of the Company, did you acquire such shares or other
securities in the ordinary course of business? 

 Yes     ̈                No     ̈ 
 At the time of purchase of such shares or other securities, did you
have any agreements or understandings, directly or indirectly, with any person to distribute the shares or other securities? 
  

 3 

 Yes     ̈                No     ̈ 
 If yes, please describe such agreements or understandings: 
                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

	4.	Transactions Relating to Company Common Stock. 

  

	 	(a)	State whether the undersigned Selling Securityholder has or will enter into “hedging transactions” with respect to shares of Common Stock. 

 Yes     ̈                No     ̈ 

If yes, you must provide a complete description of the hedging transactions into which the undersigned Selling Securityholder has entered or will enter
and the purpose of such hedging transactions, the extent to which such hedging transactions remain in place: 
                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

 Please note that the Commission may deem short sales of securities covered by a registration statement prior to the effectiveness of such
registration statement as a violation of Section 5 of the Securities Act. 
  

	 	(b)	State whether the undersigned Selling Securityholder has sold any of the Registrable Securities or shares of common stock of the Company short since the date of original issuance of
the Registrable Securities. 

 Yes     ̈                No     ̈ 
 If yes, you must provide a complete description of the short sale,
including the number of shares of common stock of the Company involved and whether the short position remains in place: 
                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

 4 

	5.	Broker-Dealer Status. 

  

	 	(a)	Are you a broker-dealer? 

 Yes     ̈                No     ̈ 

 

	 	Note:	If yes, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

  

	 	(b)	Are you an affiliate of a broker-dealer? 

 Yes     ̈                No     ̈ 

For purposes of this Item (5)(b), an “affiliate” of a broker-dealer shall include any company that, directly or indirectly through one or
more intermediaries, controls, or is controlled by, or is under common control with, such broker-dealer, and does not include any individuals employer by such broker-dealer or its affiliates. 
  

	 	(c)	If you are an affiliate of a broker-dealer, do you certify that you bought the Registrable Securities in the ordinary course of business, and at the time of the purchase of the
Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities? 

 Yes     ̈                No     ̈ 

 

	 	Note:	If no, the Commission’s staff has indicated that you should be identified as an underwriter in the Registration Statement. 

  

	 	(d)	State whether the undersigned Selling Securityholder received Registrable Securities as compensation for underwriting activities: 

 Yes     ̈                No     ̈ 

If yes, you must provide a complete description of the circumstances: 
                                       
                                        
                                        
                                        
                                        
                                        

                                       
                                        
                                        
                                        
                                        
                                        

  

	6.	Relationships with the Company. 

 Except as set
forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material
relationship with the Company (or its predecessors or affiliates) during the past three years. 
 State any exceptions here: 
                                       
                                        
                                        
                                        
                                        
                                        
           
                                       
                                        
                                        
                                        
                                        
                                        
           
  

 5 

 By signing below, the Selling Securityholder acknowledges that it understands its obligation to comply,
and agrees that it will comply, with the prospectus delivery and other provisions of the Securities Act and the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder, particularly Regulation M. 
 In the event that the Selling Securityholder transfers all or any portion of the Registrable Securities listed in Item (3) above after the date on
which such information is provided to the Company, the Selling Securityholder agrees to notify the transferee(s) of its rights and obligations under this Selling Securityholder Questionnaire and the Registration Rights Agreement. 
 By signing below, the Selling Securityholder consents to the disclosure of the information contained herein in its answers to Items (1) through
(6) above and the inclusion of such information in the Registration Statement and related Prospectus. The Selling Securityholder understands that such information will be relied upon by the Company in connection with the preparation of the
Registration Statement and related Prospectus. 
 In accordance with the Selling Securityholder’s obligations under the Registration
Rights Agreement to provide such information as may be required by law for inclusion in the Registration Statement, the Selling Securityholder agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein
which may occur subsequent to the date hereof at any time while the Registration Statement remains in effect and to provide any additional information as the Company reasonably may request. Except as otherwise provided in the Registration Rights
Agreement, all notices hereunder and pursuant to the Registration Rights Agreement shall be made in writing, by hand-delivery, first-class mail, or air courier guaranteeing overnight delivery as follows: 
  

	 	(i)	To the Company: 

 Synova Healthcare Group, Inc. 

Rose Tree Corporate Center 
 1400 N.
Providence Road 
 Suite 6010, Building II 
 Media, PA 19063 
 Attention: Stephen King 
  

	 	(ii)	With a copy (which shall not constitute notice) to: 

 Blank
Rome LLP 
 One Logan Square 
 Philadelphia, PA 19103 
 Attention: Alan L. Zeiger, Esquire 
 Once this Notice and Questionnaire is executed by the Selling Securityholder and received by the Company, the terms of this Selling Securityholder
Questionnaire, and the representations and warranties contained herein, shall be binding on, shall inure to the benefit of and shall be enforceable by the respective successors, heirs, personal representatives, and assigns of the Company and the
Selling Securityholder (with respect to the Registrable Securities beneficially owned by such Selling Securityholder and listed in Item (3) above). This Agreement shall be governed in all respects by the laws of the State of Nevada. 

 

 6 

 If you need more space for any response, please attach additional sheets of paper and indicate your
name and item number. Please also execute each such additional sheet. 
 IN WITNESS WHEREOF, the undersigned, by authority duly
given, has caused this Selling Securityholder Questionnaire to be executed and delivered either in person or by its duly authorized agent. 
  

									
	Dated:
                                        ,
2006	 		 	 SELLING SECURITYHOLDER
 (Print/type
full legal name of beneficial owner of Registrable Securities)

				
		 		 	By:	 	  
					
		 		 		 	Name:	 	  
					
		 		 		 	Title:	 	  

 PLEASE RETURN THE COMPLETED AND EXECUTED SELLING SECURITYHOLDER QUESTIONNAIRE FOR RECEIPT ON OR
BEFORE                     , 2006 TO THE COMPANY AT: 
 Synova Healthcare Group, Inc. 
 Rose Tree Corporate Center 
 1400 N. Providence Road 
 Suite 6010, Building
II 
 Media, PA 19063 
 Attention:
Stephen King 
 with a copy (which shall not constitute notice) to: 
 Blank Rome LLP 
 One Logan Square 
 Philadelphia, Pennsylvania 19103 
 Attention: Alan L. Zeiger, Esquire 
  

 7 

 Exhibit 1 to Selling Securityholder 
 Notice and Questionnaire 
 NOTICE OF TRANSFER PURSUANT TO REGISTRATION
STATEMENT 
 Synova Healthcare Group, Inc. 
 Rose Tree
Corporate Center 
 1400 N. Providence Road 
 Suite 6010, Building
II 
 Media, PA 19063 
 Attention: Stephen King 
  

	 	Re:	Synova Healthcare Group, Inc. (the “Company”) 

 Common Stock, par value $0.00 I per share (the “Stock”) 
 Dear Sirs: 
 Please be advised that
                                        
has transferred                      shares of the Company’s common stock pursuant to an effective Registration Statement on Form SB-2
(File No. 333 -                     ) filed by the Company. 
 We hereby certify that the prospectus delivery requirements, if any, of the Securities Act of 1933, as amended, have been satisfied with respect to the
transfer described above and that the above-named beneficial owner of the common stock is named as a selling securityholder in the Prospectus dated
                    , 2006 or in amendments or supplements thereto, and the number of shares of common stock transferred are [a portion of]
the shares of common stock listed in such Prospectus, as amended or supplemented, opposite such owner’s name. 
  

			
		 	Dated:
		
		 	Very truly yours,
		
		 	  
		 	(Name)

  

					
			
		 	By:	 	  
		 		 	(Authorized Signature)Distribution Agreement

 EXHIBIT 10.12 
 CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED PORTIONS ARE MARKED AS “[XXXX]” INDICATING THAT THE INFORMATION HAS BEEN OMITTED PURSUANT
TO A REQUEST FOR CONFIDENTIAL TREATMENT. AN UNREDACTED COPY OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. 
 DISTRIBUTION AGREEMENT 
 This Distribution Agreement (this “Agreement”) is made on this 22nd day of December, 2005 by and between Common Sense Ltd. (“Common Sense”), a company organized and existing under the laws of the State of
Israel of 7 Ha-Eshel St. P.O. Box 3567 Caesarea Industrial Park, Caesarea 38900; and Synova Healthcare, Inc. (the “Distributor”), a company organized and existing under the laws of the State of Delaware, U.S.A., of 1400 North
Providence Road, Suite 6010, Media, Pennsylvania, U.S.A. 19063 (collectively, the “Parties”). 
 WITNESSETH:

 WHEREAS Common Sense is the proprietary owner of the Components and the Products, and wishes to appoint a distributor for the
promotion, marketing and sale of the Products in the Territory, as those terms are defined below; and 
 WHEREAS the Distributor is
knowledgeable and experienced in the promotion, marketing and sale of certain health care products in the Territory, and is capable of and interested in distributing the Products in the Territory. 
 NOW, THEREFORE, in consideration of the foregoing and of the promises, agreements, representations, warranties, and covenants herein contained,
the Parties hereby agree as follows: 
 1. Definitions. 
 When capitalized, the following terms shall have the following meanings for the purposes of this Agreement: 
  

			
	 “FDA Clearance”
	  	The approval by the U.S. Food and Drug Administration for selling and marketing a particular product in the Territory.
		
	 “Competing Product”
	  	Any product not manufactured or distributed by Common Sense that is the same as or substantially

 2 
  

			
		  	similar to the Product(s) or is considered by end-users to be a substantially similar alternative to the Product(s).
		
	 “VI-SENSE TPL”
	  	A diagnostic Panty-Liner with an embedded strip for detection of vaginal infections.
		
	 “Drying Unit”
	  	Drying unit for the VI-SENSE TPL.
		
	 “Components”
	  	The VI-SENSE TPLs and the Drying Units.
		
	 “Set of Components”
	  	One VI-SENSE TPL and one Drying Unit.
		
	 “Products”
	  	The product(s), as set forth in Annex A to this Agreement.
		
	 “Exclusivity Targets”
	  	The targets and the exclusivity quantities set forth in Annex B.
		
	 “Territory”
	  	United States of America, Canada, and Mexico.

 2. Scope of Agreement and Appointment. 
 2.1. Common Sense hereby appoints the Distributor as its exclusive distributor of the Products in the Territory for the Term of this Agreement. The
Distributor hereby accepts the appointment and undertakes to act faithfully and diligently as Common Sense’s exclusive distributor of the Products in the Territory. 
 2.2. The Distributor’s exclusivity is conditional upon its achieving the Exclusivity Targets. In the event that the Distributor fails to achieve any one of the Exclusivity Targets, Common Sense shall be entitled
to cancel, at its sole discretion (a) the Distributor’s exclusivity and/or (b) this Agreement, each upon thirty (30) days prior written notice; provided however that if within such thirty (30) day period (x) the
Distributor achieves the Exclusivity Target, or (y) the Distributor provides Common Sense with adequate justifications (acceptable to Common Sense in its sole discretion) for the Distributor’s failure to achieve the Exclusivity Target, the
Distributor’s exclusivity, or this Agreement as applicable, shall continue to be in effect; provided, further, however, if Common Sense fails to prosecute or otherwise abate any actual or potential infringement, interference, or
misappropriation of any right, title, or interest in or to the Products or Components in the Territory, Common Sense shall not have the right to cancel or terminate Distributor’s exclusivity and/or this Agreement, but only to the extent that
such actual or potential infringement, interference, or misappropriation is the direct cause to Distributor’s failure to meet the applicable Exclusivity Target. 
 2.3. Notwithstanding the foregoing, even if the Distributor achieves the Exclusivity Targets, Common Sense shall be entitled to cancel, at its sole discretion (a) the Distributor’s exclusivity and/or
(b) this Agreement, each at any time upon thirty (30) days prior written notice (collectively the “Early Termination”), provided that it pays to the Distributor an early termination fee to be determined as follows
(“Early Termination Fee”): 

 3 
  

 2.3.1. If the effective date of said Early Termination occurs on or before
December 31, 2006, provided that the US$[XXXX] have been paid as the down payment as stated below, Common Sense shall pay the Distributor an early termination fee equal to [XXXX] ([XXXX]) times the Qualified Expenses accrued as of the effective
date of said Early Termination. 
 2.3.2. If the effective date of said Early Termination occurs on or after January 1,
2007 and before December 31, 2007, Common Sense shall pay the Distributor an early termination fee equal to (i) [XXXX] ([XXXX]) times the Qualified Expenses accrued as of the effective date of said Early Termination if, at such time, the
Products are sold in at least [XXXX] Points of Sale (or such lower number of Points of Sale as agreed upon by the parties), OR, (ii) [XXXX] ([XXXX]) times the Qualified Expenses accrued as of the effective date of said Early Termination if, at
such time, the Products are sold in less than [XXXX] Points of Sale (or such lower number of Points of Sale as agreed upon by the parties in writing). 
 2.3.3. If the effective date of said Early Termination occurs on or after January 1, 2008 and before June 30, 2008, Common Sense shall pay the Distributor an early termination fee equal to (i) [XXXX]
([XXXX]) times the Qualified Expenses accrued as of the effective date of said Early Termination if, at such time, the Products are sold in at least [XXXX] Points of Sale (or such lower number of Points of Sale as agreed upon by the parties), OR,
(ii) [XXXX] ([XXXX]) times the Qualified Expenses accrued as of the effective date of said Early Termination if, at such time, the Products are sold in less than [XXXX] Points of Sale (or such lower number of Points of Sale as agreed upon by
the parties in writing). 
 2.3.4. If the effective date of said Early Termination occurs on or after June 30, 2008,
Common Sense shall pay the Distributor an early termination fee equal to [XXXX] ([XXXX]) times the gross sales of Products by the Distributor during the 12-month period immediately preceding the effective date of Early Termination. 
 2.3.5. Notwithstanding the foregoing, it is agreed that the Early Termination Fee calculated in Sections 2.3.1-2.3.3 above shall not
exceed a cap amount equal to: (i) US$[XXXX] – for Early Termination occurring on or before March 31, 2006; or (ii) US$[XXXX] and an additional amount of US$[XXXX] per month commencing on April 1, 2006 (or a pro-rata amount
for the portion of the partial month, if applicable) – for Early Termination occurring on or after April 1, 2006. 
 2.3.6. For the purpose of this Agreement the term “Qualified Expenses” shall mean (a) direct expenses paid and amounts incurred by the Distributor for advertising, sales and marketing, and other promotional activities
with respect to the Products (“Marketing Expenses”), and (b) indirect and other direct expenses paid and amounts incurred by the Distributor otherwise in connection with this Agreement or for the purposes of performing its
obligations under this Agreement (“Other Expenses”), provided that (i) to the extent such Qualified Expenses were not incurred solely in connection with such activities, this Agreement, or such obligations, the allocation by
the Distributor of such expenses or amounts to “Qualified Expenses” shall be reviewed and audited by a reputable independent accounting firm, (ii) in no event shall the amount of Other Expenses payable 
  
 "[XXXX]" indicates information that has been omitted pursuant to a request for
confidential treatment. An unredacted copy of this Exhibit has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 

 4 
  

 
by Common Sense to Distributor under this Section exceed twenty percent (20%) of the Marketing Expenses in such period, and (iii) the Marketing
Expenses and the Other Expenses are identified in financial statements (or portions thereof) that are submitted by the Distributor to Common Sense for June 30th and December 31st of each calendar year (or such other
frequency as is consistent with Distributor’s accounting and financial practices), where such statements are audited by Distributor’s outside accounting firm (which statements, for the avoidance of doubt, shall be deemed to be
Distributor’s Confidential Information, except that Common Sense shall, to the extent such is permitted under the terms of the NDA, attached hereto as Annex E, be entitled to disclose such report to its outside accounting firm and
legal advisors for the purpose of enforcing the terms of this Agreement). The Distributor will use its reasonable efforts to provide to Common Sense, on a monthly or quarterly basis, a report related to expenses incurred by Distributor in the
marketing and promotion of the Products; provided, however, any failure by Distributor to provide reports as described herein shall not be a breach of this Agreement. 
 For the purpose of this Agreement the term “Point of Sale” shall mean a retail location. 
 2.4. Scope of Agreement. The Distributor will purchase from Common Sense the Components in bulk, prepare the packaging and labeling materials and
assemble and package the Components and Product Leaflet into final Products, and distribute and sell the Products in the Territory; all as fully set forth in this Agreement. 
 2.5. Future Products. 
 2.5.1. VS-SENSE. Common Sense acknowledges that the Distributor is interested in discussing with Common Sense the possibility of distributing its product known as VS-SENSE under terms and conditions to be agreed upon by the Parties.
The Distributor acknowledges that Common Sense is currently conducting administrative arrangements in order to conducting clinical trials in the Territory, for the purpose of obtaining FDA Clearance to VS-SENSE. If and at such time as it is
commercially reasonable to do so, the Parties shall engage in good faith negotiations regarding the terms and conditions pursuant to which the Distributor will have the right to distribute VS-SENSE in the Territory. For the avoidance of doubt, it is
clarified, that Common Sense shall be entitled to negotiate such agreement with other third parties, and nothing in this Section 2.5.1 shall be deemed to impose any restriction or limitation on Common Sense’s activities or business
endeavors in any manner, time, or place, other than to engage in good faith negotiations as set forth in this Section 2.5.1. 
 This Section 2.5.1 shall expire on September 30, 2007. 
 2.5.2. AL-SENSE. Common Sense acknowledges
that the Distributor is interested in discussing with Common Sense the possibility of distributing its product known as AL-SENSE under terms and conditions to be agreed upon by the Parties. The Distributor acknowledges that Common Sense is currently
negotiating with a potential distributor regarding distributing in the Territory AL-SENSE. If Common Sense and the potential distributor fail to enter into an agreement pursuant to which the potential distributor will distribute AL-SENSE in the
Territory, the Parties shall engage in good faith negotiations regarding the terms and conditions pursuant to which the Distributor will have the right to distribute AL-SENSE in the Territory. For the 

 5 
  

 
avoidance of doubt, it is clarified, that Common Sense shall be entitled to negotiate such agreement with other third parties, and nothing in this
Section 2.5.2 shall be deemed to impose any restriction or limitation on Common Sense’s activities or business endeavors in any manner, time, or place, other than to engage in good faith negotiations as set forth in this
Section 2.5.2. 
 This Section 2.5.2 shall expire on September 30, 2007. 
 2.5.3. NORMA-SENSE. The Distributor acknowledges that Common Sense is currently developing a product referred to as NORMA-SENSE, a
testing panty-liner intended for inserting in regular panty-liner packages, indicating whether the pH level of the secretion is elevated. NORMA-SENSE is substantially different than VI-SENSE, and thus is not expected to infer any degradations to
VI-SENSE sales. The Distributor further acknowledges that NORMA-SENSE will be relevant only to distributors of regular panty-liners. The Distributor will be considered as a relevant potential distributor of NORMA-SENSE, if it will or does market on
behalf of or represent an experienced significant market-share holder in the regular panty-liner industry. Subject to the above, if at such time, when Common Sense wishes to distribute NORMA-SENSE in the Territory, it will be commercially reasonable
to commence negotiations, the Parties shall engage in good faith negotiations regarding the terms and conditions pursuant to which the Distributor will have the right to distribute NORMA-SENSE in the Territory. For the avoidance of doubt, it is
clarified, that Common Sense shall be entitled to negotiate such agreement with other third parties, and nothing in this Section 2.5.3 shall be deemed to impose any restriction or limitation on Common Sense’s activities or business
endeavors in any manner, time, or place, other than to engage in good faith negotiations as set forth in this Section 2.5.3. 
 This Section 2.5.3 shall expire on September 30, 2007. 
 3. Forecasts, Orders, and Shipment. 
 3.1. Ninety (90) days before the commencement of each calendar year (other than the first calendar year, with respect to which the timing shall be as
separately agreed by the Parties), the Distributor shall submit to Common Sense a non-binding quarterly forecast of its projected requirements for the Components for the following year (the “Projected Requirements”). 
 3.2. Other than for the first calendar year (with respect to which the timing shall be as separately agreed by the Parties), Distributor will provide
Common Sense with a firm written order for the Components (the “Order”) within not more than one hundred fifty (150) days and not less than one hundred twenty (120) days prior to the desired delivery date and each Order
shall specify desired delivery date and the quantities of the Components ordered. However, quantities ordered by the Distributor that exceed the Projected Requirements by more than ten percent (10%) for the relevant Component and time
period shall be delivered within timetable to be mutually agreed upon by the Parties. 
 3.3. All Orders placed by the Distributor shall
become part of this continuing Agreement, and shall be subject to the terms and conditions of this Agreement. Unless otherwise agreed by the Parties, in the event of inconsistencies between the terms and conditions in this Agreement and terms and
conditions in any Order, this Agreement shall prevail. Any cancellation and/or modification of any term of an issued Order shall require both Parties’ prior written approval. 

 6 
  

 3.4. Simultaneously with the signature of this Agreement, the Distributor will issue an order for the
first four (4) deliveries of Components identified in Annex B (that is: the Initial order for [XXXX] Sets of Components to be delivered by March 31, 2006; order for [XXXX] Sets of Components to be delivered by June 30, 2006; order for
[XXXX] Sets of Components to be delivered by September 30, 2006; order for [XXXX] Sets of Components to be delivered by December 31, 2006), in the form attached hereto as Annex D, provided that, without derogating from any
other right to which Common Sense may be entitled to under this Agreement and/or applicable law, Common Sense is not required to make delivery until Distributor has paid the $[XXXX] down payment pursuant to Section 4.3. 
 3.5. All orders shall be supplied and delivered DDU (Distributor’s warehouse in the U.S. or the U.S. one warehouse of Distributor’s designee
(“Delivery Destination”)) (incoterms 2000). The minimum quantity of each order shall be [XXXX] Sets of Components. All Components supplied to the Distributor shall have an expiration date of at least forty (40) months after the
date of delivery of such Components to the Distributor, unless otherwise agreed upon by Common Sense and the Distributor in writing. 
 3.6.
Common Sense shall supply all confirmed Orders for Components submitted by the Distributor (or Orders that Common Sense is required under this Agreement to confirm), in accordance with such Orders. Each Order supplied by Common Sense shall be
accompanied by a batch quality control report. 
 4. Price and Payment. 
 4.1. For each Set of Components delivered, the Distributor shall pay Common Sense the applicable fees (plus VAT as required under applicable law) set
forth in Annex C attached hereto. 
 4.2. Except for the first order of [XXXX] Sets of Components (identified in Annex B as the “Initial
order”), Common Sense will invoice Distributor upon delivery of the Components, net 45 days. All payments hereunder shall be made in US Dollar by wire transfer into Common Sense’s account in Israel to be announced to Distributor by Common
Sense in writing from time to time. Common Sense will issue an order confirmation within three (3) working days from the acceptance of an Order. (Common Sense will accept all Orders for Components of quantities not exceeding the Projected
Requirements by more than ten percent (10%), provided that such Orders are submitted in accordance with this Agreement.) 
 4.3. On or before
the date of this Agreement, Distributor will pay Common Sense a down payment in an amount of US$[XXXX], against which Common Sense is to credit Distributor’s purchases of Components. 
  
 "[XXXX]" indicates information that has been omitted pursuant to a request for confidential treatment. An unredacted copy of this Exhibit
has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment. 

 7 
  

 For the avoidance of doubt, it is clarified that the Order for the first four (4) deliveries
described in Section 3.4 shall be irrevocable, unless this Agreement is cancelled or terminated by Common Sense under Sections 2.3 or 16.2, or by the Distributor under Sections 16.2 or 16.3. 
 4.4. If the Distributor fails to pay any applicable consideration due to Common Sense, promptly and when due, Common Sense may recover, in addition to
the applicable consideration, interest thereon at a rate equal to the lesser of 1.5% per month or the maximum lawful monthly interest rate, without prejudice to any other remedy Common Sense may be entitled. 
 4.5. All consideration set forth in this Agreement and its Annexes are exclusive of all taxes, including customs duties, import taxes and sales, use or
value added taxes where applicable. Upon presentation of invoices by Common Sense, except as otherwise provided in this Agreement the Distributor shall pay any and all applicable tariffs, duties or taxes imposed or levied by any government or
agency, including, without limitation, national, provisional and local sales, use, and value added taxes. Any claimed exemption from such tariffs, duties or taxes must be supported by a tax exemption certificate and other proper documentary evidence
delivered to Common Sense. The taxes and other amounts referenced in this paragraph shall not include any taxes based on Common Sense’s net income. The Parties hereby acknowledge that the arrangement described herein constitutes solely a
distribution agreement with respect to the sale of certain products and shall be treated for all foreign, federal, state and local income tax reporting purposes on a basis consistent with such characterization. 
 4.6. If the Distributor is legally required to withhold any income or remittance tax from amounts payable to Common Sense, then (a) the Distributor
will promptly notify Common Sense, (b) the amount payable will be automatically increased to the full extent required to offset such tax, so that the amount remitted to Common Sense, net of all taxes, equals the amount stated in the invoice,
and (c) the Distributor will provide Common Sense with the official receipt of payment of such taxes to the appropriate taxing authority. The Distributor will be responsible for payment of any withholding taxes and shall indemnify Common Sense
from and against any claim for unpaid withholding taxes, interest and penalties which may be claimed by the applicable tax authorities relating to payment of such taxes. 
 5. The Distributor’s Declarations and Covenants. 
 The Distributor declares and warrants that:

 5.1. It is not prohibited or limited by any law or agreement to which it is a party from entering into this Agreement, and the performance
of this Agreement will not create any conflict with any other business or activity engaged in by the Distributor. The Distributor further declares and warrants that it has the necessary resources, facilities, personnel and experience to perform all
its obligations under this Agreement. 
 5.2. It is not a representative, agent, or distributor for any Competing Products. The Distributor
shall not act as a representative, agent, or distributor with respect to any Competing Products, during the term of this Agreement and for additional period of twenty-four (24) months after its expiration or termination for any reason (the
“Additional Term”). In the event that Common Sense cancels the exclusivity of the Distributor in pursuant to sections 2.2 or 2.3, the Additional Term shall commence on the date of such cancellation. 

 8 
  

 5.3. It will sell and distribute the Products in accordance with any applicable law and regulations and
only after the receipt of all the required approvals and authorizations required under the applicable law. 
 5.4. It will refrain from using
either of the Components in any way whatsoever other than for packaging them into Products in accordance with the Product Specification specified in Annex A, and pursuant to the terms of this Agreement. 
 5.5. It will not change the Product Specifications without Common Sense’s prior written approval. 
 6. The Distributor’s Undertakings. 
 During the term of this Agreement the Distributor shall faithfully and diligently perform its obligations as a distributor of the Products in the Territory, and use its reasonable efforts to promote and increase the sale of the Products,
including without limitation: 
 6.1. Refrain from exporting any of the Components and/or Products outside the Territory, and refrain from
selling any of the Components and/or Products, directly or indirectly, to any customer that the Distributor has reason to believe intends to export the Components and/or Products outside the Territory; 
 6.2. Refrain from acting outside the Territory in any way whatsoever with respect to the Components and/or Products; 
 6.3. Maintain adequate levels of inventory of the Components and Products to meet its anticipated requirements for the Products from the customers in the
Territory; 
 6.4. Refrain from having any other person or company distribute the Products for it without Common Sense’s prior written
approval; 
 6.5. Appoint and maintain appropriate professional personnel to direct and handle its activities as a distributor for the
Products and provide its personnel with adequate facilities with respect to the performance of its obligations hereunder; 
 6.6. Report to
Common Sense as soon as reasonably possible (and in the event of complaint and/or demand - no later than 15 days) of any feedback, complaint, and/or demand received from customers regarding the Products; 
 6.7. Appoint a product manager who will also be the contact person with Common Sense. Until a notice of any other person appointed, Stephen King shall be
the product manager and contact person on behalf of the Distributor; and 
 6.8. Promptly submit to Common Sense written reports about
(a) new developments in the relevant market within the Territory and economy, (b) changes of the law in the Territory, which are pertinent to the use and sale of the Products in the Territory, (c) Competing Products in the Territory,
and (d) products which may infringe Common Sense’s intellectual property rights. 

 9 
  

 
Without derogating of the above, such reports shall be submitted to Common Sense at least once in each quarter; provided, however, any failure by Distributor
to provide reports as described herein shall not be a breach of this Agreement. 
 7. Handling, Storage, Manufacture. 
 7.1. The Distributor shall store the Components and the Products in adequate enclosed storage facilities and observe all applicable local laws and
regulations pertaining to their storage and handling. The Distributor shall also adhere strictly to any commercially reasonable instructions provided by Common Sense in writing in advance concerning the handling and storage of the Components and the
Products, although nothing herein shall be deemed to require Common Sense to provide such instructions. The Distributor shall manage inventory so as to ensure that the Components and the Products are utilized on a first-in-first-out
(“FIFO”) method. 
 7.2. The Distributor shall take all actions required under applicable law (including FDA regulations) in the
Territory for the performance of its obligations under this Agreement, including without limitation, to the extent required of Distributor hereunder, transporting, storing, assembling, packaging, preparing and manufacturing the labeling materials
(including, without limitation, the package and the leaflet) for, and selling the Products. 
 7.3. Common Sense shall manufacture the
Components and assist Distributor in amending the Product leaflet in accordance with all applicable laws and regulations, including, without limitation, the current and any future quality system and good manufacturing practices regulations under 21
C.F.R. Part 820, as amended, to the extent that such regulations are applicable to the Components, as such regulations are implemented by the United States Food and Drug Administration or any successor agency thereof, but without derogating from
Section 16.2. 
 7.4. The Distributor shall assemble and package the Components to Products in accordance with all applicable laws and
regulations, including, without limitation, the current and any future quality system and good manufacturing practices regulations under 21 C.F.R. Part 820, as amended, to the extent that such regulations are applicable to the Products, as such
regulations are implemented by the United States Food and Drug Administration or any successor agency thereof. 
 7.5. To the extent that
Common Sense is to use particular art work created by or licensed to the Distributor from third parties, in connection with the packaging of the Products, unless otherwise agreed upon by the Parties the Distributor will specify and provide Common
Sense with (and, as between the Distributor and Common Sense, will own all right, title, and interest in and to) such art work (“Distributor Art Work”). 
 7.6. The Distributor will notify Common Sense of any Component received at the Delivery Destination that does not conform to the Component Specifications set forth in Annex A or is the subject of a manufacturing or
other defect occurring after receipt at the Delivery Destination, or of any shortage in quantity of any Component shipment, (each, if occurring before delivery by Common Sense, a “Rejection Event”), within thirty (30) days
after the Distributor’s receipt of such shipment or, if later, within 

 10 
  

 
thirty (30) days after the date the Distributor discovers the non-conformance, defect, or shortage, provided that Distributor shall not have a claim for
a shortage if it does not notify Common Sense within 180 days of Distributor’s receipt of such shipment. Common Sense shall, in its discretion and at its sole cost and expense either, replace all such non-conforming or defective Component or
make up the shortage within thirty (30) days of receiving notice and the non-conforming or defective Components (if any) of the Rejection Event from the Distributor. Common Sense shall make arrangements with the Distributor for the return or
destruction of any non-conforming or defective Component, such return shipping charges to be paid by Common Sense. 
 7.7. Common Sense, anyone on its behalf (if such 3rd party is approved by
Distributor, such approval not to be withheld unreasonably), and any regulatory authorities may, to the extent reasonably necessary or to the extent required by applicable laws or regulations, examine and inspect the Distributor’s facilities
required for performance of its obligations hereunder (including without limitation, the assembly, packaging the Components). Any and all such examinations shall be conducted at Common Sense’s sole cost and expense, during Distributor’s
normal business hours, after at least thirty (30) days’ advance written notice, in accordance with generally accepted auditing standards, and, unless otherwise required by law or regulations, not more than once per calendar year.

 7.8. The Distributor shall prepare and maintain complete and accurate written records relating to its obligations hereunder (including
without limitation, the assembly and packaging of the Components, to the extent required hereunder). The Distributor will retain all such records that it has to retain under any applicable laws or regulations, for such periods as such laws or
regulations require. After the termination of such applicable retention periods, the Distributor shall no longer have any duty whatsoever to retain any such materials. 
 8. Products’ Packaging and Labeling. 
 8.1. The Distributor shall be responsible for packaging the
Components into final Products in accordance with the Products Specification specified in Annex A. The Distributor shall provide Common Sense for its approval (which approval shall not be withheld unreasonably) the layout of the
labeling materials and packages and Product Leaflets. However, it is the Distributor’s sole obligation to assure that the labeling materials and packaging, including without limitation, the layout of the Products’ packaging, and Product
Leaflets will satisfy all standards and regulations requirements under the applicable law. 
 8.2. The Distributor undertakes to examine and
inspect (i) all Components before assembling and packaging the Products, and (ii) all Products and packages of the final Products prior to actual distribution the Products, so as to reasonably prevent the distribution of damaged or
defective Products. The Distributor shall sell and distribute the Products only for the use as printed on the Product labels made and provided in accordance with this Agreement, and shall meet all laws, regulations and accepted industry standards
for distributors regarding traceability of Products, if necessary for Recall (as defined in Section 11.4) purposes. 

 11 
  

 9. Title and Risk. 
 9.1. Risk of loss or damage to the Components shall pass to the Distributor upon delivery at the Delivery Destination. 
 9.2. Title in the Products shall pass only after Common Sense received all fees due for such Components pursuant to Section 4.1, as specifically set forth in Annex C. 
 10. Trademarks and Trade names. 
 10.1. The
Distributor shall sell, promote and solicit orders for the Products only under the trade names and trade marks set forth in Annex A or such other trade names owned by Distributor to be agreed upon by the Parties in writing (“Distributor
Marks”). The Distributor shall retain all rights, title and interests in and to the Distributor Marks, including without limitation any trademark, copyright, trade secret or other proprietary rights of any kind therein, and, unless and to
the extent otherwise separately agreed upon by the Parties in writing, Common Sense shall have no right, and is granted no right, to use any Distributor Marks. 
 10.2. Any trade name and/or trademark that was used for a Product shall not be used by the Distributor for any Competing Product during the term of this Agreement and for additional period of two (2) years after
its termination/expiration for any reason whatsoever. 
 11. Registration of Products and FDA. 
 11.1. Common Sense has completed the general FDA certification activities and received the FDA Clearance to the Products. The Distributor shall be
responsible to complete all local registration and activities required for the distribution and sale of the Products in Mexico and Canada. All registrations and governmental authorizations of the Products, including the local authorizations, and the
FDA Certification, are and shall be the sole property of Common Sense. 
 11.2. Any use, in whole or in part, by the Distributor of any
registration obtained as described herein pursuant to this section in connection with any products other than the Products shall constitute a fundamental breach of this Agreement. 
 11.3. Each Party promptly and, in any event, within ten (10) days after receipt of any relevant notice or inquiry from any local, state, national,
or international regulatory agency or government department regarding the Components and/or the Products, shall inform the other in writing of such formal or informal notice or inquiry. 
 11.4. If any Product defect or any final, non-appealable governmental or court action or any Common Sense’s and/or Distributor’s voluntary
action results in: (a) the recall, destruction or withholding from market of any Product sold under this Agreement in the Territory (hereinafter “Recall”); or (b) institution of a field correction of any Product sold under
this Agreement in the Territory (hereinafter “Field Correction”), (i) Common Sense shall bear all costs and expenses of and shall be responsible for all corrective actions and agency and other communications associated with
such Recall or Field Correction to the extent such Recall and/or Field Correction results from Common Sense’s act or omission or Distributor’s act or omission taken at 

 12 
  

 
Common Sense’s written direction or instruction (“CS Recall and Field Correction”), and (ii) Distributor shall bear all costs and
expenses of and shall be responsible for all corrective actions and agency and other communications associated with such Recall or Field Correction to the extent such Recall and/or Field Correction results from Distributor’s act or omission, or
Common Sense’s act or omission taken at Distributor’s written direction or instruction (“Distributor Recall and Field Correction”). The Distributor will provide Common Sense with reasonable access to those Distributor
customers affected by the Recall or Field Correction, to the extent practicable, and all information received or compiled by the Distributor from such customers or otherwise with respect to such Recall or Field Correction, except as otherwise
prohibited by law or contract. If so requested by Common Sense, the Distributor will perform for Common Sense at Common Sense’s cost and expense, such CS Recall and Field Correction. Neither party shall initiate a Recall or Field Correction
until it has communicated its intention to the other party and provided such other party with data and information relating to the proposed Recall or Field Correction and a reasonable opportunity to evaluate and comment on its implementation.
Further, unless otherwise agreed by the Parties, (a) Common Sense will prepare the communication and Distributor will be responsible for communication to Distributor customers regarding such CS Recall and Field Correction, and
(b) Distributor will prepare and be responsible for the communication regarding all Distributor Recall and Field Corrections. All costs and expenses, including, but not limited to, the expenses of notification and destruction or return of the
defective Product, and the cost of replacement Product, paid or incurred by the Distributor relating to any CS Recall and Field Correction shall be reimbursed by Common Sense, and all costs and expenses, including, but not limited to, the expenses
of notification and destruction or return of the defective Product, and the cost of replacement Product, paid or incurred by Common Sense relating to any Distributor Recall and Field Correction shall be reimbursed by Distributor. 
 11.5. Either Party will immediately (within two (2) business days) notify the other Party in writing of any event or complaint that gives rise or
could give rise to the need to file a Medical Device Report (hereinafter, an “MDR”) within the meaning of the U.S. Federal Food, Drug and Cosmetic Act, as amended (the “Act”), with respect to any Product or the
manufacture, distribution or use thereof in accordance with the MDR regulation, 21 C.F.R. Part 803, as amended. Each Party shall be responsible for preparing and shall file any MDR that is required by law. If, as a result of any corrective action or
any final, non-appealable or non-appealed governmental or court action, an MDR is required to be issued for any Product sold hereunder, Common Sense shall bear the costs and expenses of and shall be responsible for all corrective actions associated
with such MDR to the extent that such MDR relates to the Components or Product Leaflet, and Distributor shall bear the costs and expenses of and shall be responsible for all corrective actions associated with such MDR to the extent that such MDR
relates to the packaging and/or other labeling materials required to be prepared (or actually prepared) by Distributor under this Agreement. 
 11.6. Common Sense shall promptly provide to the Distributor upon request all required Material Safety Data Sheets (“MSDS”) for any Component containing hazardous chemicals as required by international, national, state or
local law. The Distributor shall be entitled to provide such MSDS to its customers. 

 13 
  

 12. Proprietary Rights, Confidentiality and Publicity. 
 12.1. Ownership of Products. Common Sense shall retain all rights, title and interests in and to the Components and the Products (and any part
thereof) throughout the world, including without limitation any patent, copyright, trademark, trade secret or other proprietary rights of any kind therein, but, for the avoidance of doubt, excluding the Distributor Marks (and any other trademarks or
service marks owned by or licensed by a third party to Distributor), the Product packaging and labeling materials, and Distributor Art Work. Nothing herein shall be construed as granting to the Distributor any license or other right in or to any
patent, copyright, trademark, trade secret or other proprietary right of Common Sense. The Distributor shall not take any actions inconsistent with this Section 12.1. 
 12.2. Proprietary Notices. The Distributor shall not alter or remove any reasonable, and/or regulatory required identifying corporate name or
copyright, restricted rights, limited rights, proprietary rights or confidentiality notice, in each case only to the extent required by applicable law, included in or affixed to the Components and/or the Products, and any marketing, sales or
technical documentation. 
 12.3. Confidentiality. Common Sense may disclose to the Distributor from time to time during the term of
this Agreement information and material to assist the Distributor in the sale and use of the Products (the “Common Sense Information”). Unless the Parties agree otherwise in writing, the Distributor agrees that it will not use or
disclose the Common Sense Information for any purposes other than its performance of this Agreement. The Parties agree that the NDA, attached hereto as Annex E, entered between them on July 3, 2005, shall apply, mutatis mutandis, to
Common Sense Information. Without derogating of the aforementioned, and notwithstanding anything to the contrary, unless required by any applicable law and/or regulation (including under applicable securities laws and regulations) the Distributor
shall not disclose the existence and/or the terms of this Agreement until it has paid the down payment amount specified in Section 4.3. 
 12.4. Publicity. Notwithstanding anything contained in section 12.3, the Distributor agrees: (a) to allow Common Sense to list Distributor as a distributor on Common Sense’s website, in press releases, etc. that do not
imply Distributor’s endorsement of Common Sense or the Products; and (b) to allow Common Sense to use Distributor as a reference for the Products, which may include telephone references and onsite prospective client visits, upon obtaining
Distributor’s prior consent and at times that are convenient to Distributor. 
 12.5. Infringement Actions. 
 12.5.1. Should Common Sense become aware of any material infringement, interference, or misappropriation by any person or entity of any
right, title, or interest in or to the Components in the Territory (“Infringement”) or, as determined in Common Sense’s reasonable judgment, any potential Infringement, Common Sense promptly shall notify the Distributor in
writing, including in such notification all known relevant details and facts relating thereto. Common Sense shall be obligated to take all commercially reasonable steps and measures to prosecute and otherwise to abate each such Infringement, and the
Distributor will provide such reasonable assistance (at Common Sense’s expense) in connection therewith if requested by Common Sense; provided, however, that if Common Sense fails to prosecute or to take any commercially reasonable step or
measure to prosecute or abate an Infringement, or, upon inquiry, explicitly indicates in writing that it does not intend to do so, 

 14 
  

 
the Distributor has the right to do so independently upon at least 30 days prior written notice to Common Sense and will select counsel and control the
action, unless Common Sense takes the commercially reasonable steps and measures to prosecute and otherwise to abate each such Infringement within and at all times after such 30 day period. Common Sense shall take any and all commercially reasonable
steps and actions necessary and appropriate to secure all available intellectual property rights, including, without limitation, patent rights in and to the Components in the Territory. If Common Sense fails to take such steps and actions, the
Distributor shall have the right to do so upon at least 30 days prior written notice to Common Sense, and any and all intellectual property rights secured by the Distributor shall, notwithstanding anything else in this Agreement, be solely and
exclusively owned by and recorded in the name of Common Sense, and the Distributor will be reimbursed for its costs and expenses incurred in connection therewith. 
 12.5.2. The total cost of any Infringement action commenced or taken solely by Common Sense shall be borne by Common Sense and Common
Sense shall keep any recovery or damages for past infringement derived therefrom, including, without limitation, the settlement thereof. The total cost of any Infringement action commenced or taken solely by the Distributor shall be borne by the
Distributor and the Distributor shall keep any recovery or damages for past infringement derived therefrom, including, without limitation, the settlement thereof. In all actions taken jointly by the parties, the parties will share the expenses
equally and, and after the payment of the expenses, the parties shall share equally any and all funds recovered in such an action, including, without limitation, the settlement thereof. For the avoidance of doubt it is clarified that (i) the
assistance rendered by Distributor to Common Sense (at Common Sense’s expense) under Section 12.6.1 above, and (ii) the Distributor being included as a party in any suit as stated in Section 12.6.3 shall be deemed as “action
commenced or taken solely by Common Sense” and not be deemed as “actions taken jointly by the parties”. 
 12.5.3. In any Infringement suit or other action as either party may institute to prosecute, perfect, protect, enforce or exercise the rights in or to the Components and/or the Products granted under the terms of this Agreement or any
intellectual property rights therein or thereto, the other party hereto shall, at the request and expense of the party initiating such suit or taking such action, cooperate in all reasonable respects, including, without limitation, to the extent
possible making available relevant non-privileged records, papers, information, samples, specimens, and the like. Such cooperation shall include, without limitation, if reasonable to do so, the Distributor being included as a party in any suit to
enforce or defend any intellectual property rights, without expense to the Distributor, and Common Sense being joined or named as a party to or bringing any such suit at the request of the Distributor for standing or other applicable purposes,
without expense to Common Sense. 
 13. Warranties and Claims. 
 13.1. Common Sense warrants to Distributor that the Components supplied to the Distributor hereunder, when used properly in accordance with their instructions and until their expiry date, shall conform to the
Components Specification thereof contained in Annex A (“Component Warranty”). If the Distributor provides a warranty to its customers and/or end-users other than the 

 15 
  

 
aforesaid warranty (or the translated version thereof) or any other warranties that are not approved in writing and in advance by Common Sense (the
“Distributor Warranty”), Common Sense shall not be liable to the Distributor or any other person for any damage or loss of whatsoever nature resulted from such Distributor Warranty and the Distributor will assume full liability and
indemnify and save Common Sense harmless against any and all loss, damage or expense of any kind arising out of any claim made against Common Sense by any person, which is in excess of the warranties of Common Sense contained in this section 13.1.

 13.2. The Distributor shall give Common Sense written notice of breaches of the Component Warranty as soon as practicable after the
Distributor has learned of the facts giving rise to such breaches. 
 13.3. It is hereby specifically agreed by the Parties that the
obligation of Common Sense contained in section 7.5, above, is Common Sense’s sole obligation, responsibility and liability for a breach of the above Component Warranty, but does not limit or restrict in any respect any obligation,
responsibility, and/or liability of Common Sense under Section 15 in connection therewith. Common Sense shall not be responsible or liable to the Distributor or any other person for any damage or loss of whatsoever nature due to a breach of
such warranty other than as stated in section 7.5 above or as provided under Section 15. 
 13.4. Except as otherwise required by
applicable law, Common Sense shall have no liability hereunder to the extent of any claim based upon (i) addition to or modification of the Components and/or the Products (other than additions or modifications made by or at the written
direction or with the written approval of Common Sense); (ii) Product’s labeling materials which was prepared by the Distributor or by Common Sense in accordance with or using information or data provided in writing by Distributor (except
if prepared by Distributor in accordance with or using information or data provided in writing by Common Sense); or (iii) misuse, unauthorized use or negligent use of the Components and/or the Products and/or use of the Components/Products
after their expiration date. 
 13.5. Disclaimer of Warranties. Except for the express warranties set forth in this Section 13,
Common Sense makes no other warranties regarding the Components. To the maximum extent permitted by applicable law, the express warranties set forth in this Section 13 are the only warranties made by Common Sense with respect to the Components.
Common Sense makes no other warranties, whether express, implied, statutory or arising by custom, trade usage or course of dealing, and specifically makes no warranty of merchantability, satisfactory quality or fitness for any particular purpose.

 13.6. Common Sense warrants that (a) Common Sense has the full corporate power and authority to enter into this Agreement, and to
make the promises and to grant the rights set forth in this Agreement, and that there are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement and the Agreement is enforceable against
Common Sense in accordance with its terms, (b) the Components have passed the safety test required by the FDA, and (c) Common Sense has good and marketable title to the Components, which shall be transferred to the Distributor as set forth
in Section 9.2 above. 

 16 
  

 13.7. The Distributor will not remove the Components from the packaging and shall distribute the Products
in accordance with their Specification attached in Annex A, and shall not alter or remove Components’ packages and/or Common Sense’s notices (of which Common Sense has notified Distributor in advance), as delivered by Common
Sense. 
 14. Limitation of Liability. 
 14.1. Except in the case of fraud of a Party under this Agreement, in no event will either Party be liable to the other for any incidental, indirect, special or consequential damages, including, but not limited to, damages to goodwill, loss
of use, revenues, profits or savings in connection with this Agreement. For the avoidance of doubt, any and all Indemnifiable Expenses (as defined in Section 15.1) paid by an Indemnitee (as defined in Section 15.5) to a third party arising
from or in connection with a Claim (as defined in Section 15.1) that is indemnifiable under this Agreement shall not, for the purposes of this Agreement, be considered or deemed to be incidental, indirect, special or consequential damages.

 14.2. Except in the case of fraud, any indemnification obligation of a Party under this Agreement, or non payment of amounts due hereunder
by Distributor for Components ordered, notwithstanding any other provision of this Agreement, each Party’s total liability to the other (whether in contract, tort (including negligence) or otherwise) for any claims, liabilities, damages or
causes of action arising out of or relating to this Agreement shall not exceed the fees paid or payable by the Distributor to Common Sense during twelve (12) months preceding the date the liability arose. 
 14.3. Each Party shall maintain during the entire term of this Agreement such insurance coverage against its liabilities under this Agreement as is
commercially reasonable and sufficient under the circumstances. 
 15. Indemnification. 
 15.1. Common Sense shall indemnify, hold harmless, and defend the Distributor from and against any and all liabilities, losses, obligations, damages,
costs and expenses (including, without limitation, reasonable attorneys’ fees and payments to third parties to cover, if so required, such third parties’ consequential damages) (collectively, “Indemnifiable Expenses”)
arising from any claim, demand or allegation of third parties (collectively, “Claims”) arising from or based upon (i) any allegation by third parties that the Components or the exercise of any rights therein granted to
Distributor under this Agreement infringe or misappropriate any third party’s copyright, patent, trade secret or other intellectual property right, or (ii) any use of the Components in accordance with the Component/Product’s labeling
that directly or indirectly causes or contributes to the injury or death of or bodily harm to any individual, provided that these Claims do not arise from or are based upon a breach of Distributor’s obligations hereunder. 
 15.2. In addition to Common Sense’s indemnification obligations listed above, in the event any Component, in Common Sense’s opinion, is in fact
likely to or does become the subject of a claim of infringement, Common Sense shall have the right at its sole option and expense to: (i) replace or modify the infringing Component to be non-infringing, provided that such modification does not
materially change the performance of the Component; (ii) obtain for the Distributor a license to continue with the sale 

 17 
  

 
of the infringing Components, or if such options are not available (iii) terminate this Agreement and promptly refund to the Distributor all amounts
paid to Common Sense for the infringing Components returned to Common Sense by the Distributor in response to a timely request by Common Sense for such return. 
 15.3. The obligations of Common Sense set out in Sections 15.1 and 15.2 above constitute the Distributor’s sole remedy with respect to all such Claims. 
 15.4. The Distributor shall indemnify, defend and hold Common Sense harmless from any and all Indemnifiable Expenses imposed or brought against Common
Sense arising from any Claim that (a) any of the Distributor Marks infringes any third party’s rights, (b) any use of the Products in accordance with the Product’s labeling prepared by Distributor under this Agreement, or by
Common Sense in accordance with written instruction from Distributor, that directly or indirectly causes or contributes to the injury or death of or bodily harm to any individual, to the extent that these Claims arise from or are based upon a breach
of Distributor’s obligations hereunder, and, for the avoidance of doubt, except if such Claims are directly or indirectly caused by or based upon information or data provided in writing by Common Sense, and (c) any defect in the Components
and/or the Products resulted from Distributor’s act or omission including failure to perform its obligations to assemble, package, transfer, prepare the Product leaflet, labeling materials of, and/or store the Components and/or the Products as
required herein. The obligations of Distributor set out in this Section 15.4 above constitute Common Sense’s sole remedy with respect to all such Claims. 
 15.5. The obligations of the Party obligated to provide indemnification (the “Indemnitor”) under this section 15 are conditioned upon the other Party (the “Indemnitee”)
(a) promptly notifying the Indemnitor of any claim being the subject of indemnity which has come to the Indemnitee’s knowledge, (b) affording to the Indemnitor the sole right to assume the defense (and the eventual settlement) of any
such claim, and (c) giving the Indemnitor all available information, assistance (at the Indemnitor’s expense), and authority to enable the Indemnitor to assume such defense. The Indemnitor will have control of the defense of any such suit,
including appeals from any judgment therein and any negotiations for the settlement or compromise thereof; provided, however, the Indemnitor shall not settle, compromise, or consent to the entry of any judgment in respect of any claim with respect
to which it is obligated to provide indemnification under this Agreement without the advance written consent of the Indemnitee (which consent shall not be withheld unreasonably), to the extent the settlement, compromise, or judgment would require
the Indemnitee to incur any liability, to incur any obligation, to admit any liability, or to suffer any negative impact or adverse affect, other than the payment of money indemnified for hereunder. 
 16. Term and Termination. 
 16.1. This
Agreement shall be effective as of the date hereof and shall continue to be in effect until December 31, 2010 (the “Initial Term”), unless terminated earlier in accordance with sections 2.2, 2.3, 15.2(iii), 16.2, or 16.3. The
Distributor shall be entitled to renew the Agreement for one (1) renewal term of two (2) calendar years (i.e. for the years 2011-2012) (the “Consecutive Term”), by providing Common Sense with one hundred eighty
(180) days prior written notice, provided however that (a) the Distributor achieved all Exclusivity Targets during the Initial Term or any Consecutive Term as applicable and (b) the Parties reached an agreement regarding Exclusivity
Targets and prices, which shall apply during the Consecutive Term. 

 18 
  

 16.2. Notwithstanding paragraph 16.1 above, either of the Parties shall be entitled to terminate this
Agreement upon thirty (30) days prior written notice in the event that a law or regulation have been imposed (a) on the subject matter of this Agreement including the Components and/or the Products, or (b) on either of the Parties,
and such law or regulation which renders the execution or performance of this Agreement impossible. 
 16.3. Notwithstanding paragraph 16.1
above, each party shall have the right to terminate this Agreement at any time upon thirty (30) days prior written notice to the other party in any of the following events, provided that if the following events shall be rescinded within thirty
(30) days of their commencement, such notice of termination shall have no effect: 
 16.3.1. Bankruptcy, or other similar
or related proceedings shall be commenced with respect to the other party; 
 16.3.2. The other party shall substantially
cease to carry on business; 
 16.3.3. A substantial part of the other party’s assets shall be sold or attached or
levied by a court or another official agency; or 
 16.3.4. The other party shall be in a material breach of this Agreement.

 17. Consequences of Termination. 
 Upon expiration or termination of this Agreement for any reason the following shall apply: 
 17.1. Except as provided in section
17.6, all rights and licenses granted to Distributor hereunder shall immediately terminate. 
 17.2. The Distributor shall immediately return
to Common Sense the Common Sense Information and any other data or information, it received during or in connection with this Agreement and shall make no further use of such information without the written consent of Common Sense. 
 17.3. The Distributor shall immediately pay to Common Sense all unpaid amounts due under this Agreement. Common Sense shall deliver any Components
ordered by the Distributor prior to the date of termination only upon payment in full for such orders by the Distributor. The expiration or termination of this Agreement shall not relieve either party hereto of any obligation to pay any amount due
as a result of any transaction prior to the date of expiration or termination and shall not affect any other rights or liabilities of the parties which may have accrued prior to the date of expiration or termination. 
 17.4. The Parties shall continue to observe the provisions of sections 4, 5, 9, 10, 11, 12 (except for Section 12.4), 13, 14, 15, 17, 19.5, 19.6,
19.8 and 19.9, which shall remain in full force and effect, and survive the termination of all or any part of this Agreement. 

 19 
  

 17.5. Common Sense shall have the right to purchase from the Distributor, at a price equal to the
Distributor’s cost, any inventory of the Components and/or the Products in useable and merchantable condition; provided, however, for any inventory of the Components and/or the Products not so purchased by Common Sense within thirty
(30) days after termination or expiration of this Agreement, Distributor shall have the rights specified in section 17.6 below. 
 17.6.
The Distributor shall immediately cease marketing, and distribution of the Products, provided however, that in the event that the termination of the Agreement is not by Common Sense under sections 15.2(iii), 16.2 or 16.3.4, the Distributor shall be
entitled, for period of one hundred and twenty (120) days after termination or expiration of this Agreement, to sell any inventory of the Products held by the Distributor, and to exercise solely the rights directly related thereto granted under
this Agreement while this Agreement was in effect (in accordance with the limitations otherwise set forth in this Agreement). 
 17.7. The
Distributor hereby agrees and acknowledges that it has fully taken into account and considered the possibility of termination of this Agreement pursuant to sections 2.2, 2.3, 15.2 and 16 and that upon any such termination it shall not have any right
or entitlement for any compensation, payment or demand of any kind arising out of or in connection with such termination, or with respect of loss of anticipated income or profit or for capital investments in its business or in the promotion of the
Products in the Territory. 
 18. Force Majeure. 
 18.1. To the extent that any Party is unable, wholly or in part, by reason of Force Majeure to carry out any obligation under this Agreement, the obligation shall be suspended so far as it is directly affected by such
Force Majeure during the continuance thereof, provided that the Party concerned shall: (a) give the other party written notice of such Force Majeure with reasonably full particulars thereof and, insofar as known, the probable extent to which it
will be unable to perform or be delayed in performing such obligation; and (b) use reasonable efforts to remove such Force Majeure or its effects as quickly as possible. 
 18.2. For the purpose of this section “Force Majeure” shall mean an act of God, war (declared and undeclared), army mobilization, blockade,
revolution, riot, insurrection, civil commotion, sabotage, lightning, fire, earthquake, storm, flood, explosion, strike or other labor unrest, unavailability or inability to obtain or delay in availability of necessary materials, equipment or
transport, and any other cause whether of the kind specifically enumerated above or otherwise which is not reasonably within the control of the party affected. 
 19. Other Provisions. 
 19.1. Successors and Assigns. 
 19.1.1. Common Sense may assign this Agreement to any third party, provided however that (a) such third party shall assume all the
obligations of Common Sense under this Agreement; and (b) that Distributor’s rights hereunder shall remain unaffected by such assignment. The Distributor shall not be entitled to any additional compensation as a result of such assignment.

 20 
  

 19.1.2. The Distributor may not assign or otherwise convey the rights or obligations
established under the Agreement, except to the Distributor’s affiliates, provided however that (a) such affiliate shall assume all the obligations of the Distributor under this Agreement, and (b) Common Sense shall be entitled to
terminate this Agreement upon written notice to Distributor within ninety (90) days after such assignment if such assignee is a competitor of Common Sense. For the purpose of this section, “affiliate” shall mean any entity
which, directly or indirectly, controls, is controlled by or is under common control with the Distributor or any entity with the Distributor merges or is consolidated or which acquires all or substantially all of the assets or business of the
Distributor. For purposes of the foregoing, “control” shall mean ownership of at least 51% of the equity or voting power of an entity or the right to appoint more than 51% of the members of such entity’s Board of Directors.

 19.2. No modification or waiver of any provision of this Agreement, nor consent to any departure here from shall in any event be effective
unless the same shall be in writing and signed, in the case of a modification by both parties, and in the case of consent, by the consenting party. 
 19.3. No failure in exercising any remedy or right hereunder shall be construed as a waiver of such remedy or right, nor shall any failure in exercising a right or remedy hereunder due to an instance of breach or default imply acquiescence
of such breach or default in similar situations, whether occurring theretofore or thereafter, and which may be considered in a similar manner. 
 19.4. This Agreement (including all Annexes referenced herein, which are incorporated herein and are a part hereof) constitutes the entire agreement between the Parties pertaining to the subject matter hereof and supersedes all prior
agreements (excluding the NDA entered into on July 3, 2005, by the Distributor and attached hereto as Annex E), understandings, negotiations and discussions, whether oral or written, regarding the subject matter hereof, and there are no
warranties or, representations except as contained herein. 
 19.5. This Agreement shall be governed exclusively by the laws of the State of
New York, U.S.A., without regard to its conflicts of law rules. The United Nations “Convention Relating to a Uniform Law on the International Sale of Goods” or any similar or successor convention or law, shall not be applied to this
Agreement or to transactions under this Agreement. For all disputes arising under or in connection with this Agreement, these disputes shall be exclusively referred to and finally resolved by binding arbitration conducted in accordance with the
rules of the London Court of International Arbitration (“LCIA”) and judgment upon the award rendered by the arbitral tribunal may be entered in any court having jurisdiction thereof. The arbitration tribunal shall consist of three
arbitrators. The place of arbitration shall be London. The arbitral award shall be final and binding. Each party retains the right to seek judicial assistance: (i) to compel arbitration; (ii) to obtain interim measures of protection
prior to or pending arbitration, and (iii) to enforce any decision of the arbitrator, including the final award. In addition, either Party may apply ex party to courts having jurisdiction in the matter to obtain an injunction to prevent
disclosure of its confidential information or an infringement of its intellectual property rights. Notwithstanding the foregoing, in any event that a third party files a suit against either of the Parties, such Party shall be entitled, subject to
applicable law, to send the other Party of this Agreement, a “Third Party Notice” or demand that the other Party shall participate in such process, and the provisions of section 19.5 above shall not apply. 

 21 
  

 19.6. If any term or provision of this Agreement is held by a court of competent jurisdiction and/or an
Arbitrator to be invalid, void or unenforceable, the remainder of the provisions shall remain in full force and effect and shall in no way be affected, impaired or invalidated and the parties will negotiate in good faith a substitute provision which
most nearly effects the Parties’ intent in entering into this Agreement. 
 19.7. The Parties are and shall remain independent
contractors, and nothing herein shall be construed to create a partnership or joint venture between the Distributor and Common Sense. Nothing herein shall be construed as implying that employees of either party are employees of the other party.
Neither party has the right to bind the other in any manner whatsoever and nothing in this Agreement shall be interpreted to make either party the agent or legal representative of the other. 
 19.8. The section headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. 
 19.9. Any notice, consent, offer, demand, request or other instrument required or authorized to be given to or served on
any Party hereunder shall be in the English language and in writing and may be given by facsimile transmission or e-mail or by registered or certified mail, postage prepaid, and shall be deemed sufficiently given upon receipt and shall be addressed
to the Party intended as the recipient thereof as follows- 
  

			
	 To Common Sense:
	  	To the Distributor:
	 Common Sense Ltd.
	  	Synova Healthcare, Inc.
	 7 Ha-Eshel St.
	  	1400 North Providence Road
	 P.O. Box 3567 Caesarea Industrial Park
	  	Suite 6010
	 Caesarea 38900, Israel
	  	Media, Pennsylvania 19063
		  	U.S.A.
	 Attn: Mr. Menashe Terem, CEO
	  	Attn: Mr. Stephen King, Chairman
		
	 With a copy to:
	  	With a copy to:
	 Meitar, Liquornik, Geva & Leshem, Brandwein
	  	Blank Rome LLP
	 16 Abba Hillel Silver Rd.
	  	One Logan Square
	 Ramat-Gan 52506
	  	Philadelphia, PA 19103
	 Israel
	  	U.S.A.
	 Attention: Noam Gavish, Adv.
	  	Attention: Alan L. Zeiger, Esq.

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and
delivered on the last date written below. 
  

					
	 Common Sense Ltd.
	 		  	 Synova Healthcare, Inc.

			
	  
	 	  	  	  

	 Name:
	 		  	Name:
	 Title:
	 		  	Title:
	 Date:
	 		  	Date:

 22 
  

 Annexes 
 A – The
Components, the Products, their Specifications and Trademarks 
 B – The Exclusivity Targets 
 C – Prices of Components 
 D – Order Form 
 E – NDA 

 23 
  

 Annex A 
 The Components, the Products, their Specifications and Trademarks 
 A/. VI-SENSE - Product
Specifications: 
  

			
	i.	  	1 VI-SENSE TPL wrapped in plain (unbranded) aluminum foil package.
		
	ii.	  	1 Drying Unit.
		
	iii.	  	1 Product Leaflet.
		
	iv.	  	Product Package

 Trademark and Trade name: TBA (by Distributor), excluding any trademark and/or trade name
owned by Common Sense. In no event shall Common Sense provide to Distributor any Component that contains or includes any brand, trademark, service mark, trade name, or other name, logo, slogan, or symbol of Common Sense or any other person or
entity, other than such brands, trademarks, service marks, trade names, and other names, logos, slogans, and symbols of Distributor as are identified by Distributor in writing in advance in its sole discretion. 
 B. VI-SENSE Set Specification: 
 Each Set of
Components shall include 1 VI-SENSE TPL and 1 Drying unit. 
 The Components will be delivered in bulk of 100 Sets. 
 C. Components Specification: 
 Component
dimensions: 
 TPL: Length 210 mm +/- 2 mm; Width 85 mm +/- 5mm  
 Drying Unit: Length 145 mm +/- 1mm; Width 110 mm +/- 1mm 

 24 
  

 Annex B 
 Exclusivity Targets 
 (i) Purchasing by Distributor from Common Sense the amounts of
Components specified in the column “VI-SENSE Set of Components Purchases by Distributor from Common Sense” during the periods set forth herein: 
  

				
	 Target Period
	  	VI-SENSE Set of
Components
Purchases by
Distributor from
Common Sense	 
	 Initial order/During January 1, 2006 – March 31, 2006
	  	[XXXX	]
		
	 During April 1, 2006 – June 30, 2006
	  	[XXXX	]
		
	 During July 1, 2006– September 30, 2006
	  	[XXXX	]
		
	 During October 1, 2006 – December 31, 2006
	  	[XXXX	]
		
	 During January 1, 2007 – March 31, 2007
	  	[XXXX	]
		
	 During April 1, 2007 – June 30, 2007
	  	[XXXX	]
		
	 During July 1, 2007 – September 30, 2007
	  	[XXXX	]
		
	 During October 1, 2007 – December 31, 2007
	  	[XXXX	]
		
	 During January 1, 2008 – March 31, 2008
	  	[XXXX	]
		
	 During April 1, 2008 – June 30, 2008
	  	[XXXX	]
		
	 During July 1, 2008 – September 30, 2008
	  	[XXXX	]
		
	 During October 1, 2008 – December 31, 2008
	  	[XXXX	]
		
	 During January 1, 2009 – March 31, 2009
	  	[XXXX	]
		
	 During April 1, 2009 – June 30, 2009
	  	[XXXX	]
		
	 During July 1, 2009 – September 30, 2009
	  	[XXXX	]
		
	 During October 1, 2009– December 31, 2009
	  	[XXXX	]
		
	 During January 1, 2010 – March 31, 2010
	  	[XXXX	]
		
	 During April 1, 2010 – June 30, 2010
	  	[XXXX	]
		
	 During July 1, 2010 – September 30, 2010
	  	[XXXX	]
		
	 During October 1, 2010 – December 31, 2010
	  	[XXXX	]

  
 "[XXXX]" indicates information that
has been omitted pursuant to a request for confidential treatment. An unredacted copy of this Exhibit has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment.

 25 
  

 Annex C 
 Prices of Components 
  

					
	 Component
	  	Transfer
Price DDU
(in US$)	 
	 One Set of VI-SENSE Components
	  	$	[XXXX	]

 All prices indicated above are exclusive of all taxes, including customs duties, import taxes, and
sales use or value added taxes as fully detailed in sections 4.5 and 4.6 of the Agreement. 
  
 "[XXXX]" indicates information that has been omitted pursuant to a request for confidential treatment. An unredacted copy of this Exhibit has been filed separately with the United States Securities and Exchange
Commission pursuant to a request for confidential treatment. 

 26 
  

 Annex D 
 Order Form 
  

					
	 From:                                     
                             
	 	 To: Common Sense Ltd.
 Att.
Inbal Fogel
 7 Ha-Eshel St.
 P.O. Box 3567 Caesarea
Industrial Park
 Caesarea 38900, ISRAEL

	 Date:                                     
                              
	 	Fax – 972-4-6277103

 Dear Sirs, 
 We are pleased to send you our order No.                     , as follows: 
  

					
	 VI-SENSE Sets Quantity:
	 	[XXXX]
		
	 Price:
	 	$[XXXX] USD DDU per Set
		
	 Total
	 	$[XXXX] USD
		
	 Goods destination:
	 	Our Warehouse address:
		 	  
	  	
		 	  
	  	
		 	  
	  	
		
	 Expected Delivery Date:
	 	 [XXXX]VI-SENSE Sets– March 31st, 2006
 [XXXX]VI-SENSE Sets– June 30th , 2006
 [XXXX]VI-SENSE Sets –
September 30th, 2006
 [XXXX]VI-SENSE Sets– December 31st, 2006

			
	 Invoice destination:
	 	  
	  	
		 	  
	  	
		 	  
	  	
		
	 Delivery Terms:
	 	DDU
		
	Payment Terms (subject to terms of Distribution Agreement):	 	Advanced payment $[XXXX] USD, not later than the date of the Distribution Agreement.
		
		 	Schedule payments – Net 45 days

  
 "[XXXX]" indicates information that
has been omitted pursuant to a request for confidential treatment. An unredacted copy of this Exhibit has been filed separately with the United States Securities and Exchange Commission pursuant to a request for confidential treatment.

 27 
  

 Please, confirm us this order. 
 Best regards, 
  

	
	
	  

	 Name    Position    Signature

 28 
  

 Annex E 
 NDA 
 NON-DISCLOSURE AGREEMENT 
 This NON-DISCLOSURE AGREEMENT (“Agreement”) made and entered into this 3 day of July 2005, by and between Common Sense Ltd., a company
organized under the laws of Israel (“Common Sense”) and Synova Healthcare, Inc., a company organized under the laws of the State of Delaware with offices at 1400 N. Providence Road, Suite 601, Media, PA 19063, USA (the
“Recipient”). 
 WITNESSETH 
 WHEREAS the parties may enter into discussions regarding a potential business relationship; and 
 WHEREAS Common Sense is prepared to disclose to the Recipient certain information relating to Common Sense, which Recipient is to receive solely in order to efficiently conduct the negotiations between the parties; and 
 WHEREAS the Parties wish to agree regarding the terms and conditions under which Common Sense is prepared to disclose to the Recipient the
Confidential Information (as defined below). 
 NOW, THEREFORE, IT IS HEREBY AGREED BY THE PARTIES AS FOLLOWS: 
  

	1.	DEFINITIONS. 

  

	1.1.	The term “Confidential Information” shall include and mean any and all information, data, diagrams and know-how programs furnished at any time by Common Sense to
Recipient and Associates, whether in oral, written, graphic or machine-readable form, and which is confidential or proprietary in nature or expressed or designated by Common Sense to be proprietary or confidential, whether or not owned or developed
by Common Sense, including but not limited to current or projected components, software, hardware, technical and other data, research material, Biological and Chemical materials, inventions, discoveries, drawings, plans, concepts, procedures, ideas,
diagrams, marketing plans, brochures, photographs, processes, test equipment, test data, specifications, operational data, financial data, methods and techniques. Notwithstanding any of the above said, the following shall not be considered
Confidential Information: (a) information that was in the public domain at the time it was disclosed other than as a result of a breach by Recipient; (b) information that can be demonstrated by documentary evidence to have been known to
Recipient at the time of disclosure with no obligation of confidentiality or limitation on use towards Common Sense; and (c) information that becomes known to Recipient from a source other than Common Sense and its Associates, as demonstrated
by appropriate documentation, without breach of any obligation of confidence by Recipient or by the party disclosing such information to Recipient. 

 29 
  

	1.2.	The term “Associate” shall mean, as to each party, such party’s agents, representatives, advisors, employees, directors or officers. 

 

	2.	NON-DISCLOSURE. 

  

	2.1.	General. Recipient acknowledges that the Confidential Information of Common Sense contains valuable trade and technical secrets of Common Sense. Recipient shall not copy (in
whole or in part), sell, assign, lease, license, disclose, give or otherwise transfer the Confidential Information or any copy thereof to any third party or otherwise use the Confidential Information other than for the purpose intended under this
Agreement. Recipient will not alter, modify, disassemble, reverse engineer or de-compile any software or other materials (in any form) or documents embodying Confidential Information of Common Sense which may be furnished to Recipient, without the
express prior written consent of Common Sense. Recipient may disclose the Confidential Information only to its Associates to have a “need to know” such Confidential Information in order to enable Recipient to use such Confidential
Information for the purpose intended under this Agreement and are legally bound not to use or disclose such Confidential Information for any other purpose. Without limiting any other provision hereof, Recipient will take all reasonable measures to
ensure that any of its Associates receiving Confidential Information of Common Sense shall comply with all of the provisions of this Agreement as if each of them were a party hereto, and hereby assumes full responsibility for such compliance by its
Associates. Recipient shall treat Common Sense’s Confidential Information with the same degree of confidentiality as it keeps its own Confidential Information, but in all events no less than a reasonable degree of confidentiality. Recipient
shall safeguard any and all copies of Common Sense’s Confidential Information against unauthorized disclosure, shall not tamper with, bypass or alter its security features or attempt to do so, and shall take all reasonable steps to ensure that
the provisions of this Agreement are not violated by any person under Recipient control or in Recipient service. Recipient shall not use the Confidential Information for any purpose other than the purpose set forth in this Agreement.

  

	2.2.	Exception. Disclosure of Confidential Information by Recipient if and only to the extent it is compelled to do so by final judicial or administrative order or decree, shall
not be deemed a breach hereunder. Recipient shall notify Common Sense immediately after demand for disclosure was presented to it, and shall assist Common Sense, to reasonable extent and upon reimbursement of reasonable expenses, in objecting to
such demand. 

  

	3.	PROPRIETARY NATURE. 

  

	3.1.	Ownership. All Confidential Information is and shall remain the property of Common Sense. The parties acknowledge that all Confidential Information is the sole property of
Common Sense and that Recipient shall not acquire any proprietary interest in the Confidential Information. 

  

	3.2.	 Intellectual Property. Recipient acknowledges that the Confidential Information was designed, developed or otherwise obtained at great expense over lengthy
periods of time, and that the Confidential Information is secret, confidential, unique and essential to the business of Common Sense and constitutes the exclusive property and trade secret of Common Sense. All 

 30 
  

	 	 
applicable rights to mask works, topographies, patents, copyrights, trademarks and trade secrets with respect to the Confidential Information of Common Sense
are retained exclusively by Common Sense. 

  

	3.3.	Disclaimer. Common Sense makes no representation or warranty as to accuracy, completeness, condition, suitability, or performance of the Confidential Information, and Common
Sense shall have no liability whatsoever to Recipient resulting from its use of the Confidential Information. Nothing herein shall be construed as creating any obligation on Common Sense to disclose any Confidential Information or to enter into any
agreement with Recipient on a commercial or any other basis. 

  

	 3.4.
	 Acknowledgement. AmniocheckTM Common Sense acknowledges that Recipient is in the process of developing a product known as AmniocheckTM. Nothing contained in this agreement shall be deemed to limit, restrict or prohibit the Recipient from developing, marketing, manufacturing and selling Amniocheck or any products derived thereunder.

  

	4.	Return of Confidential Information. Recipient will return all of the Confidential Information in written or other tangible form, including any copies made, to Common Sense
together with certification that any other copies or notes or summaries (to the extent including the Confidential Information) have been destroyed, promptly upon the request of Common Sense. 

  

	5.	Term and Termination. The provisions of this Agreement shall remain in full force and effect for a period of five (5) years. The provisions of Sections 1 through 5 of
this Agreement shall survive any termination. 

  

	6.	Injunctive Relief. The parties acknowledges that Common Sense will be irreparably harmed if Recipient obligations under this Agreement are not specifically enforced and that
Common Sense would not have an adequate remedy at law in the event of an actual or threatened violation by Recipient of its obligations. Therefore, in addition to all other remedies it may have, Common Sense shall be entitled to an injunction or any
appropriate decree of specific performance for any actual or threatened violations or breaches by Recipient or Recipient’s employees or agents without the necessity of Common Sense showing actual damages or that monetary damages would not
afford an adequate remedy. Recipient shall be directly liable for any and all reasonable attorney’s fees incurred by the Common Sense to enforce this Agreement against Recipient in the courts of component jurisdiction. 

 

	7.	Assignment. Recipient shall not assign or otherwise transfer any of its rights or obligations under this Agreement to any third party without the prior written consent of
Common Sense. 

  

	8.	No Waiver. Failure by a party to enforce any provisions of this Agreement at any time shall in no manner affect the right of that party at a later time to enforce any
provision of this Agreement. 

  

	9.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York. 

 31 
  

	10.	Severability. In the event that any word, phrase, clause, sentence or other provision herein shall violate any applicable statute, ordinance or rule of law in any
jurisdiction which governs this Agreement, such provisions shall be effective to the extent of such violation without invalidating any other provision herein. 

  

	11.	Entire Agreement. This Agreement supersedes all previous understandings or agreements between the parties and incorporates the entire agreement of the parties with respect to
the receipt and use of the Confidential Information. This Agreement may only be amended by a writing of subsequent date that is signed by both parties. 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth above. 
  

									
	 Common Sense Ltd.
	 		 	[...]	 	
					
	 By:
	 	 /s/ Illegible
	 		 	By:	 	 /s/ Stephen E. King

	 Name:
	 	  
	 		 	Name:	 	Stephen E. King
	 Title:
	 	CEO	 		 	Title:	 	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]